The Organising Committee gratefully acknowledges the support and collaboration of all Member Societies of ECCO, the European Cancer organisation, without which this Congress would not be possible.

Acknowledgements

Full members

European Association for Cancer Research (EANR)
European Oncology Nursing Society (EONS)
European Society for Medical Oncology (ESMO)
European Society of Surgical Oncology (ESSO)
European Society for Radiotherapy & Oncology (ESTRO)
European Society of Paediatric Oncology (SIOPE)
Breast International Group (BIG)
European Association of Nuclear Medicine (EANM)
European Group for Blood and Marrow Transplantation (EBMT)
Association of European Cancer Leagues (AECL)
European Breast Cancer Coalition (EUROPA DONNA)
European Prostate Cancer Coalition (EUROPA UOMO)
European Association of Neuro-Oncology (EANO)
European Association of Urology (EAU)
European Organisation for Research and Treatment of Cancer (EORTC)
European Society of Gynaecological Oncology (ESGO)
European School of Oncology (ESO)
European Society of Oncology Pharmacy (ESOP)
European Society of Breast Cancer Specialists (EUSOMA)
European Society of Skin Cancer Prevention (EUROSKIN)
European Myeloma Patients Organisation

Advisory members

European Prostate Cancer Coalition (EPCc)
European Society of Skin Cancer Prevention (EUROSKIN)
European Myeloma Patients Organisation

Official Media Partners

On behalf of the Executive Scientific Committee, we gratefully acknowledge the collaboration and support of our official media partners for the European Cancer Congress 2015.
Table of Contents

Acknowledgements ................................................................................................................. 3
Save the Dates .......................................................................................................................... 5
Chairs' Introduction .................................................................................................................. 6
European Cancer Congress 2015 Committees ........................................................................ 8
Opening Ceremony .................................................................................................................. 13
Programme at a Glance .......................................................................................................... 14
Detailed Advance Programme ................................................................................................. 20
Young Oncologists @ ECC2015 ............................................................................................... 60
Patient Advocacy Track .......................................................................................................... 62
Oncopolicy Track .................................................................................................................... 63
Call for Abstracts ..................................................................................................................... 64
Abstract Topic Categories ......................................................................................................... 67
Fellowship Grants and Educational Awards ........................................................................... 70
Why you should participate at ECC2015 .............................................................................. 77
Digital Scientific Programme .................................................................................................. 80
Registration .............................................................................................................................. 84
Exhibition & Sponsorship ........................................................................................................ 86
General Information ............................................................................................................... 87

Save the Dates

18th ECCO - 40th ESMO European Cancer Congress
25 – 29 September 2015

KEY DATES AND DEADLINES

<table>
<thead>
<tr>
<th>Event</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract submission opens</td>
<td>26 January 2015</td>
</tr>
<tr>
<td>Early rate registration deadline</td>
<td>9 April 2015</td>
</tr>
<tr>
<td>Abstract submission deadline</td>
<td>28 April 2015</td>
</tr>
<tr>
<td>Fellowship grant application deadline</td>
<td>5 May 2015</td>
</tr>
<tr>
<td>Late breaking abstract submission opens</td>
<td>22 July 2015</td>
</tr>
<tr>
<td>Regular rate registration deadline</td>
<td>4 August 2015</td>
</tr>
<tr>
<td>Late breaking abstract submission deadline</td>
<td>5 August 2015</td>
</tr>
<tr>
<td>Late rate registration deadline</td>
<td>18 September 2015</td>
</tr>
<tr>
<td>Congress in Vienna</td>
<td>25-29 September 2015</td>
</tr>
</tbody>
</table>

Congress Venue

Messe Wien Exhibition & Congress Centre
Messeplatz 1, 1021 Vienna, Austria
Detailed information about the venue:
www.messe.at/en

Congress Secretariat

c/o ECCO – the European CanCer Organisation
Avenue E. Mounier 83, B-1200 Brussels
Telephone: +32 (0)2 775 02 01
Fax: +32 (0)2 775 02 00
Email: ECC2015@ecco-org.eu
www.europeancancercongress.org
Chairs’ Introduction

The 18th ECCO – 40th ESMO European Cancer Congress (ECC2015) is the largest European multidisciplinary oncology platform for presenting ground-breaking data to a global audience this year.

We are on a path where each ECC Congress sets new records – increasing in the number of participants and submitted abstracts. The most recent ECC2013 in Amsterdam registered 16% growth in delegates and a massive 38% increase in the number of submitted abstracts compared to our event in Stockholm in 2011.

The European Cancer Congress is now giving fresh impetus to its unique philosophy of collaborative innovation to improve outcomes and find new solutions to pressing issues. Led by the ECC2015 Education Committee Chair, the educational programme is a result of the collaboration of all ECCO founding members, all experts in their respective fields. The programme is more streamlined, with fewer tracks, facilitating an even more productive experience for delegates. This Congress bridges basic and translational research to the clinic as research drives the change in how we treat our patients.

Topics of the greatest interest to a multidisciplinary audience will be presented by the very experts who will implement them. There are multidisciplinary tumour board sessions with a clinical orientation supported by case presentations. These sessions emulate multidisciplinary teams working in the real world and provide participants with concrete insights for immediate practical application. The scientific symposia will focus on the new developments in research and treatment that will impact the future of cancer diagnosis and care. ECC2015 will expand the much needed dialogue between basic and clinical researchers as well as the one between pathologists, molecular imaging specialists and clinicians whenever possible. The educational symposia and teaching lectures will provide state-of-the-art training in the most relevant topics in oncology at this time.

The patient perspective is at the heart of the programme and of our collaborative innovation philosophy aimed at improving outcomes and including patients in identifying breakthrough solutions. The patient voice is now even more present in scientific sessions and delivers essential understanding enabling us to learn and to provide the best possible treatment and care.

Following its record number of abstract submissions in previous congresses, ECC2015 is again opening for abstract submission in January with a deadline of 28 April 2015. Abstracts will be selected to populate the presidential and proffered paper sessions and the poster and poster discussion sessions.

Each poster session is a must-attend event with over 3000 participants viewing the posters. This year, we will host “Posters in the spotlight” where selected authors will present their data during the poster sessions. This unique viewing will take place in the poster area.

And finally our late-breaking submission policy is specially designed to ensure the Congress embraces all promising new developments to ensure a very advanced, forward-looking scientific programme.

An application has been made to the EACCME® for CME accreditation of this event.

We have enriched the programme with new elements over and above those of CME – there are unique mentorship opportunities, a special leadership programme, and a number of targeted sessions offering insights into important areas of professional development for oncologists.

ECC2015 is a unique multidisciplinary Congress with a programme looking to the future through education, research and development, changing the landscape of oncology to improve the quality of treatment and care of cancer patients.

You may now browse the details of the scientific programme for the hot topics which will be presented by leading experts in each of our 27 tracks and for all the integrated sessions making the most of promising connections in research and clinical practice.

We are confident that you will discover much to interest you and we look forward to seeing you in Vienna in September!

Martine Piccart, Congress Chair, ECCO President
Rolf A. Stahel, ESMO President
Peter Naredi, ECCO Scientific Co-Chair
Elisabeth De Vries, ESMO Scientific Co-Chair
Jean-Yves Douillard, ECC2015 Education Committee Chair
Christoph Zielinski, National Organising Committee Chair
## European Cancer Congress 2015 Committees

<table>
<thead>
<tr>
<th>Organising Committee</th>
<th>Education Committee</th>
<th>National Organising Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Martine Piccart</td>
<td>Jean-Yves Douillard</td>
<td>Christoph C. Zielinski</td>
</tr>
<tr>
<td>Rolf A. Stahel</td>
<td>Andrés Cervantes</td>
<td>Walter Berger</td>
</tr>
<tr>
<td>Peter Naredi</td>
<td>Nikolaos Pavlidis</td>
<td>Günter Gastl</td>
</tr>
<tr>
<td>Elisabeth De Vries</td>
<td>Michele Chielmini</td>
<td>Michael Gnant</td>
</tr>
<tr>
<td>Christoph Zielinski</td>
<td>Giampaolo Tortora</td>
<td>Richard Greil</td>
</tr>
<tr>
<td>Wim J.G. Oyen</td>
<td>Raffaele Califano</td>
<td>Wolfgang Hofer</td>
</tr>
<tr>
<td></td>
<td>Claus-Henning Koehne</td>
<td>Lukas A. Huber</td>
</tr>
<tr>
<td></td>
<td>Robert Eckert</td>
<td>Ulrich Jäger</td>
</tr>
<tr>
<td></td>
<td>Florian Strasser</td>
<td>Karin Kapp</td>
</tr>
<tr>
<td></td>
<td>Richard Herrmann</td>
<td>Walter Klepetko</td>
</tr>
<tr>
<td></td>
<td>Lorenz Jost</td>
<td>Ruth Ladenstein</td>
</tr>
<tr>
<td></td>
<td>Karin Haustermans</td>
<td>Peter H. Lukas</td>
</tr>
<tr>
<td></td>
<td>Linda Wyld</td>
<td>Richard Pötter</td>
</tr>
<tr>
<td></td>
<td>Verena Jendrossek</td>
<td>Maria Sabilia</td>
</tr>
<tr>
<td></td>
<td>Riccardo Riccardi</td>
<td>Hellmut Samonigg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Martin Schindl</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sebastian Schoppmann</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Felix Sedlmayer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Veronika Sexl</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Harald Titzer</td>
</tr>
</tbody>
</table>

**Names in blue denote Chairs**
## Programme Tracks, Chairs and Experts

### European Cancer Congress 2015

<table>
<thead>
<tr>
<th>Track</th>
<th>Track Names</th>
<th>Chairs and Experts</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Breast Cancer – Advanced Disease</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Breast Cancer – Early Disease</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cancer Prevention and Screening</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Central Nervous System</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Trial Design and Regulatory Affairs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Early Drug Development</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Gastrointestinal Malignancies – Colorectal Cancer</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Gastrointestinal Malignancies – Noncolorectal Cancer</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Gynaecological Malignancies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Head and Neck Cancer</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Haematological Malignancies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Immunotherapy of Cancer</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Innovations in Radiation Oncology</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Oncology Nursing</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Oncology Nursing</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nonprostate Cancer Malignancies – Genitourinary</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nonprostate Cancer Malignancies – Gastrointestinal</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nonprostate Cancer Malignancies – Prostate Cancer</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Programme Tracks**

- **Breast Cancer – Advanced Disease**
- **Breast Cancer – Early Disease**
- **Cancer Prevention and Screening**
- **Central Nervous System**
- **Clinical Trial Design and Regulatory Affairs**
- **Early Drug Development**
- **Gastrointestinal Malignancies – Colorectal Cancer**
- **Gastrointestinal Malignancies – Noncolorectal Cancer**
- **Gynaecological Malignancies**
- **Head and Neck Cancer**
- **Haematological Malignancies**
- **Immunotherapy of Cancer**
- **Innovations in Radiation Oncology**
- **Oncology Nursing**

**Chairs and Experts**

- **Breast Cancer – Advanced Disease**
- **Breast Cancer – Early Disease**
- **Cancer Prevention and Screening**
- **Central Nervous System**
- **Clinical Trial Design and Regulatory Affairs**
- **Early Drug Development**
- **Gastrointestinal Malignancies – Colorectal Cancer**
- **Gastrointestinal Malignancies – Noncolorectal Cancer**
- **Gynaecological Malignancies**
- **Head and Neck Cancer**
- **Haematological Malignancies**
- **Immunotherapy of Cancer**
- **Innovations in Radiation Oncology**
- **Oncology Nursing**

**Names in Blue denote Track Chairs**
Opening Ceremony

The Opening Ceremony for the European Cancer Congress will take place on Friday 25 September from 19:15 in the Congress Centre.

The keynote speech will be given by Margaret Foti, PhD, MD (hc), Chief Executive Officer of AACR and Secretary-Treasurer of the AACR Foundation. She earned a master’s degree and a doctorate in communications from Temple University in Philadelphia, Pennsylvania.

At the AACR, Margaret Foti worked collaboratively with its elected officers to provide the corporate knowledge and continuity of leadership that have been critical to the association’s progress and its mission to prevent and cure cancer. During Foti’s tenure, the AACR’s membership has grown from about 3,000 to 35,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in 97 countries. Margaret Foti has since launched seven major peer-reviewed scientific journals: Cancer Epidemiology, Biomarkers & Prevention; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research, Cancer Prevention Research; Cancer Discovery; and Cancer Immunology Research. Dr Foti also leads the AACR’s scientific partnership with Stand Up To Cancer, a charitable initiative that supports groundbreaking research aimed at getting new cancer treatments to patients in an accelerated time frame. Dr Foti is the recipient of many national and international awards for her contributions to cancer research including the European Cancer Organisation Lifetime Achievement Award.

Dr Foti will deliver a lecture focusing on “New Funding Models for Accelerating Progress Against Cancer.”

The Opening Ceremony will also feature an inspiring talk on science and music. As is customary, the National Organising Committee will introduce Vienna and Austria to the Congress participants. Prof. Dr. Klaus Laczika will present a “History of the Viennese Waltz - the Complexity of Ease - How did it all start, how did it evolve and where has it lead us?”

Following the ceremony, there will be a Networking Reception - an opportunity for Society Members and all experts participating in the Congress to meet and begin their exchange of ideas and thoughts on the latest achievements in research laboratories and clinical environments.
### Programme at a Glance

#### Legend

<table>
<thead>
<tr>
<th>Organ Sites</th>
<th>Tracks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast Cancer - Advanced Disease</td>
<td></td>
</tr>
<tr>
<td>Breast Cancer - Early Disease</td>
<td></td>
</tr>
<tr>
<td>Central Nervous System</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal Malignancies - Colorectal Cancer</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal Malignancies - Noncolorectal Cancer</td>
<td></td>
</tr>
<tr>
<td>Genitourinary Malignancies - Nonprostate Cancer</td>
<td></td>
</tr>
<tr>
<td>Genitourinary Malignancies - Prostate Cancer</td>
<td></td>
</tr>
<tr>
<td>Gynaecological Cancer</td>
<td></td>
</tr>
<tr>
<td>Head and Neck Cancer</td>
<td></td>
</tr>
<tr>
<td>Lung Cancer - Localised/Local Regional Disease</td>
<td></td>
</tr>
<tr>
<td>Lung Cancer - Metastatic Disease</td>
<td></td>
</tr>
<tr>
<td>Melanoma and Skin Cancer</td>
<td></td>
</tr>
<tr>
<td>Nursing and Supportive Care</td>
<td></td>
</tr>
<tr>
<td>Immunotherapy of Cancer</td>
<td></td>
</tr>
<tr>
<td>Immunotherapy</td>
<td></td>
</tr>
<tr>
<td>Nursing and Supportive Care</td>
<td></td>
</tr>
<tr>
<td>Oncology Nursing</td>
<td></td>
</tr>
<tr>
<td>Palliation</td>
<td></td>
</tr>
<tr>
<td>Integrated Sessions</td>
<td></td>
</tr>
<tr>
<td>Integrated Sessions</td>
<td></td>
</tr>
<tr>
<td>Research and Drug Development</td>
<td></td>
</tr>
<tr>
<td>Basic Science/Translational Research</td>
<td></td>
</tr>
<tr>
<td>Clinical Trial Design and Regulatory Affairs</td>
<td></td>
</tr>
<tr>
<td>Early Drug Development</td>
<td></td>
</tr>
<tr>
<td>Patient Advocacy and Policy</td>
<td></td>
</tr>
<tr>
<td>Cancer Prevention and Screening</td>
<td></td>
</tr>
<tr>
<td>Oncopolicy</td>
<td></td>
</tr>
<tr>
<td>Patient Advocacy</td>
<td></td>
</tr>
<tr>
<td>General</td>
<td></td>
</tr>
<tr>
<td>Industry</td>
<td></td>
</tr>
<tr>
<td>Non CME</td>
<td></td>
</tr>
</tbody>
</table>

#### Daywise Schedule

**Friday, 25 September 2015**

**Programme at a Glance**

- **Opening Ceremony**: 19:15 - 21:00

- **11:00 - 13:00**
  - Sponsored Satellite Symposium
  - 11:00 - 13:00

- **14:00 - 16:00**
  - Sponsored Satellite Symposium
  - 14:00 - 16:00

- **17:00 - 19:00**
  - Sponsored Satellite Symposium
  - 17:00 - 19:00
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Session I</td>
<td>Early Cancer Disease</td>
<td>Discusses the latest developments in early cancer disease management.</td>
</tr>
<tr>
<td>Session II</td>
<td>Cancer Nursing</td>
<td>Focuses on the role of nurses in cancer care.</td>
</tr>
<tr>
<td>Session III</td>
<td>New Tools and Approaches</td>
<td>Introduces new diagnostic and therapeutic tools.</td>
</tr>
<tr>
<td>Session IV</td>
<td>Oncology: Cancer Genetics</td>
<td>Explores the genetic basis of cancer.</td>
</tr>
<tr>
<td>Session V</td>
<td>How to Avoid Timebombs in Lung Cancer</td>
<td>Discusses common pitfalls in lung cancer treatment.</td>
</tr>
<tr>
<td>Session VI</td>
<td>Achieving Optimal Outcomes</td>
<td>Focuses on optimizing patient outcomes.</td>
</tr>
<tr>
<td>Session VII</td>
<td>Leadership</td>
<td>Discusses leadership roles in oncology.</td>
</tr>
<tr>
<td>Session VIII</td>
<td>This House Believes</td>
<td>Debates various medical hypotheses.</td>
</tr>
<tr>
<td>Session IX</td>
<td>Integrating Young Adult Cancer Care</td>
<td>Considers the integration of young adult cancer care.</td>
</tr>
<tr>
<td>Session X</td>
<td>Young Oncologists - Mentorship</td>
<td>Focuses on mentorship programs for young oncologists.</td>
</tr>
<tr>
<td>Session XI</td>
<td>Multidisciplinary Tumour Board</td>
<td>Discusses multidisciplinary approaches to cancer treatment.</td>
</tr>
<tr>
<td>Session XII</td>
<td>How to Improve Cancer Training and Career Planning?</td>
<td>Discusses strategies to improve cancer training.</td>
</tr>
<tr>
<td>Session XIII</td>
<td>Multidisciplinary Practice</td>
<td>Explores the benefits of multidisciplinary practice.</td>
</tr>
<tr>
<td>Session XIV</td>
<td>Strategies in HPV Cervical Cancer</td>
<td>Examines strategies for HPV-related cervical cancer.</td>
</tr>
<tr>
<td>Session XV</td>
<td>Non-Small Cell Lung Cancer</td>
<td>Focuses on non-small cell lung cancer.</td>
</tr>
<tr>
<td>Session XVI</td>
<td>HPV Vaccine for Cancer Prevention</td>
<td>Discusses the role of HPV vaccines in cancer prevention.</td>
</tr>
<tr>
<td>Session XVII</td>
<td>Managing Older Patients - An Increasing Challenge ?</td>
<td>Discusses the management of older cancer patients.</td>
</tr>
<tr>
<td>Session XVIII</td>
<td>Young Adult Cancer</td>
<td>Focuses on young adult cancer care.</td>
</tr>
<tr>
<td>Session XIX</td>
<td>Current Concepts in Oncology</td>
<td>Discusses current oncology concepts.</td>
</tr>
<tr>
<td>Session XX</td>
<td>This House Believes</td>
<td>Debates various medical hypotheses.</td>
</tr>
<tr>
<td>Session XXI</td>
<td>Young Oncologists - Mentorship</td>
<td>Focuses on mentorship programs for young oncologists.</td>
</tr>
<tr>
<td>Session XXII</td>
<td>Multidisciplinary Tumour Board</td>
<td>Discusses multidisciplinary approaches to cancer treatment.</td>
</tr>
<tr>
<td>Session XXIII</td>
<td>How to Improve Cancer Training and Career Planning?</td>
<td>Discusses strategies to improve cancer training.</td>
</tr>
<tr>
<td>Session XXIV</td>
<td>Multidisciplinary Practice</td>
<td>Explores the benefits of multidisciplinary practice.</td>
</tr>
<tr>
<td>Session XXV</td>
<td>Strategies in HPV Cervical Cancer</td>
<td>Examines strategies for HPV-related cervical cancer.</td>
</tr>
<tr>
<td>Session XXVI</td>
<td>Non-Small Cell Lung Cancer</td>
<td>Focuses on non-small cell lung cancer.</td>
</tr>
<tr>
<td>Session XXVII</td>
<td>HPV Vaccine for Cancer Prevention</td>
<td>Discusses the role of HPV vaccines in cancer prevention.</td>
</tr>
</tbody>
</table>
ECC2015 Detailed Advance Programme

General

Friday 25 September 2015

Opening Ceremony
19:30 - 21:00

New funding models for accelerating progress against cancer
Speaker: M. T. Ho (United States)

Details to be announced in the online searchable programme and final programme as soon as possible

Saturday 26 September 2015

Opening Plenary Session
08:45 - 10:15

Welcome by Congress President
Speaker: M. Piccart (Belgium)

Chair of EFCO Patient Advisory Committee
Panel: I. Banks (Belgium)

EONS President
Panel: E. van Muilekom (Netherlands)

EACR President
Panel: R. Stahel (Switzerland)

ESTRO President
Panel: P. Poortmans (Netherlands)

ESSO President
Panel: F. Peccatori (Italy)

EONS President
Panel: F. Stasser (Switzerland)

Leadership Programme 1
12:45 - 14:30

Chair: C. R. M. van der Velden (Netherlands)

Optimising oesophageal-gastric cancer care
Speaker: T. Offenbacher (United Kingdom)

Prospective international Watch and Wait Database (IWWD) for complete responders of neoadjuvant therapies for rectal cancer
Speaker: N. Figueras (Portugal)

Breast cancer in Europe
Speaker: D. Bates (Switzerland)

Discussion

Special Session: Women in Oncology Forum
23:00 - 14:30

Details to be announced in the online searchable programme and final programme as soon as possible

Presidential Session I
12:30 - 16:30

Keynote Lecture
Speaker: To be announced

ECCO Lifetime Achievement Award
Awardee: To be announced

Includes best and late breaking abstracts

Leadership Programme 2
14:30 - 16:30

The objective of this workshop is to learn how to be an effective leader in your institute/department

Sunday 27 September 2015

Highlight Session
08:00 - 08:45

Details to be announced in the online searchable programme and final programme as soon as possible

Scientific Symposium: ESMO Clinical Practice Guidelines
09:15 - 11:15

Chair: A. Costa (Italy)

Economics for oncologists: The reality of costs
Speaker: P. Gomez (United Kingdom)

Concerns or solutions: The ESO Innovation Task Force
Speaker: G. Pentheroudakis (Greece)

The World Oncology Forum: Treat the treatable
Speaker: F. Paciotti (Italy)

The ESMO initiative on affordable drugs
Speaker: M. Piccart (Belgium)

Affordability of innovative cancer medicine: A research perspective
Speaker: P. Voderman (United Kingdom)

Roundtable discussion with the audience

Special Session: ESMO Designated Centres of Integrated Oncology and Palliative Care
18:15 - 20:15

Chair: F. Stasser (Switzerland)

Details to be announced in the online searchable programme and final programme as soon as possible

Scientific Symposium: ESMO/SGO Joint Symposium: Geriatric Oncology - A Multidisciplinary Approach to Reinforce Positive Outcomes in Older Patients
09:15 - 10:45

Chair: M. Aapro (Switzerland)

A case among others in your MDT meeting: An 83 year old breast cancer patient
Presentation of the patient
Speaker: A. Costa (Italy)

Operating the older patient: Yes, it is possible!
Speaker: R.A. Audisio (United Kingdom)

Iradiate or not the older breast cancer patient
Speaker: M. Piccart (Belgium)

Chemotherapy: Which one and why
Speaker: S. Lüder (Germany)

But what about her quality of life?
Speaker: R. Britz (Spain)

The role of the geriatrician
Speaker: J. T. Hsu (France)

Not competing but collaborating and final words
Speaker: E. France (France)

Questions & Answers

Multiple myeloma case presentation
Speaker: To be announced

Discussion: Dr. Ahmed (Germany)

Questions & Answers

Malnutrition/cachexia case presentation
Speaker: To be announced

Discussion: Harlan Strauss (Switzerland)

Questions & Answers

Breast cancer case presentation: HER2+ metastatic disease after adjuvant trastuzumab
Speaker: E. Emmunael (Switzerland)

Discussion: Elsbetza Senkus-Konefka (Poland)

Questions & Answers

Scientific Symposium: ESMO/ESMO Pezcoller Award
Awardee: To be announced

14:45 - 16:45

Details to be announced in the online searchable programme and final programme as soon as possible

Presidential Session II
14:45 - 16:45

ECCO Pezcoller Award
Awardee: To be announced

14:45 - 16:45

Details to be announced in the online searchable programme and final programme as soon as possible

Scientific Symposium: ESMO/ESMO Hamilton-Fairly Award
Awardee: To be announced

14:45 - 16:45

Details to be announced in the online searchable programme and final programme as soon as possible

Scientific Symposium: ESMO/ESMO Leonard Armfield Award
Awardee: To be announced

14:45 - 16:45

Details to be announced in the online searchable programme and final programme as soon as possible

Scientific Symposium: ESMO/ESMO Yusuf Hamied Award
Awardee: To be announced

14:45 - 16:45

Details to be announced in the online searchable programme and final programme as soon as possible

Scientific Symposium: ESMO/ESMO Kenneth B. Davis Award
Awardee: To be announced

14:45 - 16:45

Details to be announced in the online searchable programme and final programme as soon as possible

Scientific Symposium: ESMO/ESMO Freireich Award
Awardee: To be announced

14:45 - 16:45

Details to be announced in the online searchable programme and final programme as soon as possible

Scientific Symposium: ESMO/ESMO Outstanding Investigator Award
Awardee: To be announced

14:45 - 16:45

Details to be announced in the online searchable programme and final programme as soon as possible

Roundtable: Oncology Drum Development in the Era of Genomic Sequencing
13:00 - 14:30

Chair: J. C. Santa (France)

Academic perspective
Speaker: D. Salis (Italy)

Industry perspective
Speaker: A. Hour (USA)

FDA perspective
Speaker: P. Curtiss (USA)

EMA perspective
Speaker: P. Pigatto (United Kingdom)

Patient advocate perspective
Speaker: J. Booth (France)

Paediatric oncologist perspective
Speaker: R. Kalesnik (Australia)

Discussion
Tuesday 29 September 2015

**Highlight Session**

- **08:00-08:45**
  Details to be announced in the online searchable programme and final programme as soon as possible

**INTEGRATED**

**Sunday 27 September 2015**

**Integrated Session: Treating Lymphoid Malignancies in Children and Adults with the Same Protocols**
- **09:45 - 11:15**
  Chair: M. Pfreundschuh (Germany)
  Co-Chair: C. Menn (Australia)
  Introduction
  Speaker: M. Pfreundschuh (Germany)
  Burkitt’s lymphoma in children
  Speaker: A. van den Coven (France)
  Burkitt’s lymphoma in adults
  Speaker: T. Yamaguchi (Germany)
  Lymphoblastic leukaemia in children
  Speaker: M. Heyman (Sweden)
  Lymphoblastic leukaemia in adults
  Speaker: B. Biessy (France)
  Discussion & Roundup

**Integrated Session: Personalising Treatment Modalities in Locally Advanced Rectal Cancer**
- **16:45 - 18:45**
  Chair: R.A. Stahel (Switzerland)
  Co-Chair: J. Vansteenkiste (Belgium)
  Introduction
  Speaker: A.F. Sobrero (Italy)
  How to involve the primary care physician in survivor care for growing number of survivors
  Speaker: F. Ciardiello (Italy)
  Patients in control of navigating their own survivor care plan
  Speaker: J. Gietema (Netherlands)
  Discussion & Roundup

**Monday 28 September 2015**

**Integrated Session: Novel Approaches to Brain Metastases**
- **09:45 - 11:15**
  Chair: S. Gamba (Germany)
  Co-Chair: A. Enzi (Romania)
  Biology of brain metastases
  Speaker: P.J. Stood (USA)
  Novel systemic therapy approaches to brain metastases: Lung
  Speaker: S. Popat (United Kingdom)
  Novel systemic therapy approaches to brain metastases: Breast
  Speaker: M. Preusser (Australia)
  Advances in loco-regional treatments
  Speaker: M. Brandi (United Kingdom)
  Tolerability of brain metastasis treatments
  Speaker: S. Deffertti (Italy)
  Response assessment in brain metastases
  Speaker: N. Lin (USA)
  Discussion & Roundup

**Integrated Session: How to Personalise Treatment Modalities in Locally Advanced Rectal Cancer**
- **16:45 - 18:45**
  Chair: A.F. Sobrero (Italy)
  Co-Chair: A. J. de Haes (United Kingdom)
  Introduction
  Speaker: A.F. Sobrero (Italy)
  By imaging
  Speaker: G. Brown (United Kingdom)
  By drug combination
  Speaker: B. Glynne-Jones (France)
  By modulation radiotherapy volume and dose
  Speaker: C. Mynieux (Netherlands)
  By supporting decision tools
  Speaker: S. Jakim (Italy)
  Discussion & Roundup

**Integrated Session: Medulloblastoma**
- **16:45 - 18:45**
  Chair: S. Rutkowski (Germany)
  Co-Chair: R. Gospodarowicz (France)
  Introduction
  Speaker: S. Rutkowski (Germany)
  Molecular classification of medulloblastoma
  Speaker: S. Pfeifer (France)
  Current concepts and future directions in pharmacotherapy of medulloblastoma
  Speaker: B. Gospodarowicz (France)
  Recent results and current concepts for risk adapted medulloblastoma treatment: Experiences from the German HIT-studies and the SIOP - Europe PNET working group
  Speaker: S. Rutkowski (Germany)
  Optimising efficacy and limiting radiotherapy for medulloblastoma
  Speaker: S. Combs (Germany)
  Management of adult medulloblastoma - using the evidence from children and adolescents
  Speaker: A.A. Brat (France)
  Discussion & Roundup

**Tuesday 29 September 2015**

**Integrated Session: Immunotherapy in NSCLC - 2015**
- **09:00 - 11:00**
  Chair: L. Paz-Ares (Spain)
  Co-Chair: M. Reck (Germany)
  Introduction
  Speaker: L. Paz-Ares (Spain)
  Lung cancer: An immunogenic tumour?
  Speaker: A. Quaas (United Kingdom)
  Any place for vaccination strategies?
  Speaker: J. van den Bogaert (Belgium)
  Check point inhibitors – where do we stand and where are we going?
  Speaker: M. Reck (Germany)
  Biomarkers - a realistic perspective?
  Speaker: R. Kerr (United Kingdom)
  Discussion & Roundup
Scientific Symposium: Cellular Immunotherapy of Cancer

20:30 - 22:00

Chair: J. Melero (Spain)
Co-Chair: C. Caldas (United Kingdom)

Molecular basis for radiotherapy in synergy with immunotherapy
Speaker: S. Demaria (USA)

Radiotherapy, immunotherapy and virotherapy riddles
Speaker: K. Harrington (United Kingdom)

Learning radioimmunotherapy
Speaker: P. Beckhove (Germany)

Discussion & Roundup

Special Session: Precision Medicine and New Drugs for the Treatment of Children and Adolescents with Cancer

15:45 - 16:15

Chair: L. Cortes (Italy)
Co-Chair: J. Garrido (Spain)

Tumour molecular profiling to guide new drug development: Experiences from Germany, France, UK and Netherlands
Speaker: S. Vassal (France)

Making the most of dendritic cell-based immunotherapy
Speaker: C. Figlar (Netherlands)

Making the most of dendritic cell-based immunotherapy
Speaker: C. Figlar (Netherlands)

Is cancer immunosurveillance relevant?
Speaker: J. Calon (France)

Monoclonal antibodies in paediatric acute leukaemias
Speaker: A. Von Stechow (Germany)

Discussion & Roundup

Special Session: Combining Radiation and Immunotherapy

17:45 - 18:15

Chair: A. Melcher (United Kingdom)

Molecular basis for radiotherapy in synergy with immunotherapy
Speaker: S. Demaria (USA)

Radiotherapy, immunotherapy and virotherapy riddles
Speaker: K. Harrington (United Kingdom)

Learning radioimmunotherapy
Speaker: P. Beckhove (Germany)

Discussion & Roundup

Special Session: Successes and Uncertainties for Targeted Therapies of Sarcomas

18:45 - 19:15

Chair: J. Blay (France)

Trabectedine and M2 macrophages
Speaker: M. D’Incalci (Italy)

MDM2/CDK4: Good targets?
Speaker: G. Demetri (USA)

CSF1R Ab or Ib
Speaker: G. Demetri (USA)

Discussion

Scientific Symposium: Emerging Developments and Treatment Strategies in HPV Positive Head and Neck Cancer

16:45 - 18:15

Chair: L. Licitra (Italy)
Co-Chair: U. Keilholz (Germany)

Genomic landscape of HPV related head and neck cancer
Speaker: C. H. Chung (U.S.)

HPV targeted therapies in HPV associated oropharynx cancer
Speaker: A. Eggermont (France)

EGFR targeted approaches in HPV related head and neck cancer: is there any role?
Speaker: L. Cortes (Italy)

Deintensification strategies in HPV positive oropharynx tumours
Speaker: P. Lassen (Denmark)

Discussion & Roundup

Scientific Symposium: New Trends in Molecular Targeting for Radiation Oncology

16:45 - 18:15

Chair: Y. Shih (Israel)
Co-Chair: B. Conroy (Canada)

Immunotherapy and radiation therapy
Speaker: E. Deutsch (France)

The link between receptors and signalling pathways and radiation therapy
Speaker: K. Harrington (United Kingdom)

Angiogenesis and tumour vasculature influences radiation effects
Speaker: M. Pruschy (Switzerland)

Why DNA repair is so important for radiation oncologists
Speaker: T. Helleday (Sweden)

Discussion & Roundup

Scientific Symposium: Childhood Cancer: Bad Luck or Bad Genes?

18:45 - 19:15

Chair: J. Brugieres (France)
Co-Chair: M. Deenick (UK)

Status of predisposition to paediatric malignancies: The known and unknown
Speaker: K. Wimmer (Austria)

Dysregulated RAS signalling in paediatric cancer and developmental disorders
Speaker: M. Tartaglia (Italy)

Li-Fraumeni syndrome
Speaker: A. Melcher (France)

Discussion & Roundup

Scientific Symposium: New Drugs on the Horizon I

19:15 - 20:45

Chair: M. Schilling (Netherlands)
Co-Chair: H. Zwierzina (Austria)

Melanoma: Immunotherapy, TKIs, chemotherapy, combinations? What’s next?
Speaker: C. Blank (Netherlands)

Lung cancer: New targets, new drugs, will we eventually even improve survival?
Speaker: M. O’Byrne (United Kingdom)

Myelodysplastic syndrome: The epigenetic model for drug development?
Speaker: G. Garcia-Manero (USA)

Discussion & Roundup

Educational Symposium: Advances in Cancer Therapy Through Modulation of the Immune System

09:15-11:15

Chair: B. Van den Eynde (Belgium)

Role of the immune system on the outcome of cancer therapy
Speaker: G. Coukos (Switzerland)

How does ionising radiation contribute to the induction of anti-tumour immunity?
Speaker: C. Multhoff (Germany)

Targeting tumour microenvironment
Speaker: P. Allavena (Italy)

Adoptive cell therapy
Speaker: R. Hawkins (United Kingdom)

Discussion & Roundup

Translational Aspects of Metastatic Breast Cancer: Developments in the Treatment of Metastatic Breast Cancer: Translational Aspects

15:45 - 18:15

Chair: A. Psyrri (Greece)
Co-Chair: W. Eberhardt (Germany)

Renal Cell Carcinoma: What Can We Expect for the Future?
Speaker: A. Psyrri (Greece)

Immunotherapy and radiation therapy
Speaker: E. Deutsch (France)

The link between receptors and signalling pathways and radiation therapy
Speaker: K. Harrington (United Kingdom)

Angiogenesis and tumour vasculature influences radiation effects
Speaker: M. Pruschy (Switzerland)

Why DNA repair is so important for radiation oncologists
Speaker: T. Helleday (Sweden)

Discussion & Roundup

Scientific Symposium: Childhood Cancer: Bad Luck or Bad Genes?

17:45 - 18:15

Chair: L. Licitra (Italy)
Co-Chair: U. Keilholz (Germany)

Genomic landscape of HPV related head and neck cancer
Speaker: C. H. Chung (U.S.)

HPV targeted therapies in HPV associated oropharynx cancer
Speaker: A. Eggermont (France)

EGFR targeted approaches in HPV related head and neck cancer: is there any role?
Speaker: L. Cortes (Italy)

Deintensification strategies in HPV positive oropharynx tumours
Speaker: P. Lassen (Denmark)

Discussion & Roundup

Scientific Symposium: New Trends in Molecular Targeting for Radiation Oncology

16:45 - 18:15

Chair: Y. Shih (Israel)
Co-Chair: B. Conroy (Canada)

Immunotherapy and radiation therapy
Speaker: E. Deutsch (France)

The link between receptors and signalling pathways and radiation therapy
Speaker: K. Harrington (United Kingdom)

Angiogenesis and tumour vasculature influences radiation effects
Speaker: M. Pruschy (Switzerland)

Why DNA repair is so important for radiation oncologists
Speaker: T. Helleday (Sweden)

Discussion & Roundup

Scientific Symposium: Childhood Cancer: Bad Luck or Bad Genes?

18:45 - 19:15

Chair: J. Brugieres (France)
Co-Chair: M. Deenick (UK)

Status of predisposition to paediatric malignancies: The known and unknown
Speaker: K. Wimmer (Austria)

Dysregulated RAS signalling in paediatric cancer and developmental disorders
Speaker: M. Tartaglia (Italy)

Li-Fraumeni syndrome
Speaker: A. Melcher (France)

Discussion & Roundup

Scientific Symposium: New Drugs on the Horizon I

19:15 - 20:45

Chair: M. Schilling (Netherlands)
Co-Chair: H. Zwierzina (Austria)

Melanoma: Immunotherapy, TKIs, chemotherapy, combinations? What’s next?
Speaker: C. Blank (Netherlands)

Lung cancer: New targets, new drugs, will we eventually even improve survival?
Speaker: M. O’Byrne (United Kingdom)

Myelodysplastic syndrome: The epigenetic model for drug development?
Speaker: G. Garcia-Manero (USA)

Discussion & Roundup

Educational Symposium: Advances in Cancer Therapy Through Modulation of the Immune System

09:15-11:15

Chair: B. Van den Eynde (Belgium)

Role of the immune system on the outcome of cancer therapy
Speaker: G. Coukos (Switzerland)

How does ionising radiation contribute to the induction of anti-tumour immunity?
Speaker: C. Multhoff (Germany)

Targeting tumour microenvironment
Speaker: P. Allavena (Italy)

Adoptive cell therapy
Speaker: R. Hawkins (United Kingdom)

Discussion & Roundup

Translational Aspects of Metastatic Breast Cancer: Developments in the Treatment of Metastatic Breast Cancer: Translational Aspects

15:45 - 18:15

Chair: A. Psyrri (Greece)
Co-Chair: W. Eberhardt (Germany)

Renal Cell Carcinoma: What Can We Expect for the Future?
Speaker: A. Psyrri (Greece)

Immunotherapy and radiation therapy
Speaker: E. Deutsch (France)

The link between receptors and signalling pathways and radiation therapy
Speaker: K. Harrington (United Kingdom)

Angiogenesis and tumour vasculature influences radiation effects
Speaker: M. Pruschy (Switzerland)

Why DNA repair is so important for radiation oncologists
Speaker: T. Helleday (Sweden)

Discussion & Roundup

Scientific Symposium: Childhood Cancer: Bad Luck or Bad Genes?

17:45 - 18:15

Chair: L. Licitra (Italy)
Co-Chair: U. Keilholz (Germany)

Genomic landscape of HPV related head and neck cancer
Speaker: C. H. Chung (U.S.)

HPV targeted therapies in HPV associated oropharynx cancer
Speaker: A. Eggermont (France)

EGFR targeted approaches in HPV related head and neck cancer: is there any role?
Speaker: L. Cortes (Italy)

Deintensification strategies in HPV positive oropharynx tumours
Speaker: P. Lassen (Denmark)

Discussion & Roundup

Scientific Symposium: New Trends in Molecular Targeting for Radiation Oncology

16:45 - 18:15

Chair: Y. Shih (Israel)
Co-Chair: B. Conroy (Canada)

Immunotherapy and radiation therapy
Speaker: E. Deutsch (France)

The link between receptors and signalling pathways and radiation therapy
Speaker: K. Harrington (United Kingdom)

Angiogenesis and tumour vasculature influences radiation effects
Speaker: M. Pruschy (Switzerland)

Why DNA repair is so important for radiation oncologists
Speaker: T. Helleday (Sweden)

Discussion & Roundup

Scientific Symposium: Childhood Cancer: Bad Luck or Bad Genes?

18:45 - 19:15

Chair: J. Brugieres (France)
Co-Chair: M. Deenick (UK)

Status of predisposition to paediatric malignancies: The known and unknown
Speaker: K. Wimmer (Austria)

Dysregulated RAS signalling in paediatric cancer and developmental disorders
Speaker: M. Tartaglia (Italy)

Li-Fraumeni syndrome
Speaker: A. Melcher (France)
Special Session: How to Use Omics Data for Precision Radiation Oncology

13:00 - 14:00
Chair: D. Zips (Germany)
How to bring “radio-omics” and functional tests in the clinic
Speaker: B. Wouters (Canada)
Systems biology for precision radiation oncology: Moving between the forest and the trees
Speaker: Y. Shiloh (Israel)
Implications of new knowledge for trial design
Speaker: A. Hre In (Norway)
Discussion
**ECCO 18 - ESMO 40 - European Cancer Congress - ADVANCE PROGRAMME**

**Special Session: The Prerequisite for Ideal Biobanking**
- **07:45 - 08:15**
  - Chair: J. Driessen (Belgium)
  - **How much is important for the basic research the material and the dataset?**
    - Speaker: E. Camara (Portugal)
  - **From the operating room to the laboratory. The value of surgery standardisation and data collection in a tissue bank**
    - Speaker: S. Cansi (Italy)
  - **Interventional radiologist (please suggest your title)**
    - Speaker: J. Futterer (Netherlands)

**Discussion**
- **08:15 - 09:00**
  - **Scientific Symposium: Evolution of Targeted Therapies in Lung Cancer: Where Are We Today and Where Are We Going?**
    - Chair: S. Popat (United Kingdom)
    - Co-Chair: R. Buettner (Germany)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Chair</th>
<th>Co-Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 11:00</td>
<td>One size doesn’t fit all - current status of commonly used surrogate markers across tumours: Paradigms from colorectal, lung and breast cancer</td>
<td>M. Reck (Germany)</td>
<td>A. M. M. Eggermont (France)</td>
</tr>
<tr>
<td>11:15 - 12:15</td>
<td>Companion diagnostic co-development in personalised medicine (including circulating tumour cells)</td>
<td>L. L. Su (Canada)</td>
<td></td>
</tr>
<tr>
<td>12:30 - 13:30</td>
<td>In MRD a valid surrogate endpoint for evaluation of new drugs in lung cancer?</td>
<td>M. Giaccone (Italy)</td>
<td></td>
</tr>
</tbody>
</table>

**Discussion & Roundup**
- **Tuesday 29 September 2015**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Chair</th>
<th>Co-Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 10:30</td>
<td>Scientific Symposium: Optimal Treatment of Luminal Breast Cancer: Emerging Data on Improving Response to Hormone Therapy</td>
<td>M. Martin (Spain)</td>
<td>S. A. W. Fuqua (USA)</td>
</tr>
<tr>
<td>10:45 - 12:15</td>
<td>Immunogens and immunostimulatory monoclonal antibodies</td>
<td>R. Dummer (Switzerland)</td>
<td>C. Robert (France)</td>
</tr>
<tr>
<td>12:30 - 13:30</td>
<td>Melanoma targeted therapies in the interface with immunotherapy</td>
<td>A. Abbas (USA)</td>
<td></td>
</tr>
<tr>
<td>13:45 - 15:15</td>
<td>Virotherapy and immunotherapy</td>
<td>C. A. B. Fletcher (United Kingdom)</td>
<td></td>
</tr>
</tbody>
</table>

**Discussion & Roundup**
- **15:15 - 16:15**
  - **Scientific Symposium: High-Tech Innovations for Precision Radiation Oncology: Concept, Status and Clinical Benefit**
    - Chair: D. Kmetz (France)
    - **How can protons contribute to radiation oncology**
      - Speaker: M. Schultze (Australia)
    - **Might it be heavier? Irradiation with carbon and other ions**
      - Speaker: R. Diogo (Italy)
    - **How to get most out of photon based radiation therapy**
      - Speaker: D. Vreven (Belgium)
    - **MR-Linac is a way to improve treatment delivery**
      - Speaker: M. Van Veen (Netherlands)

**Educational Symposium: Common Approaches & Pathways in Adult and Paediatric Malignancies**
- **09:00 - 10:00**
  - Chair: R. Riccardi (Italy)
  - **Biomarkers - a realistic perspective?**
    - Speaker: K. Karr (United Kingdom)
  - **Discussion & Roundup**

**Integrated Session: Immunotherapy in the Management of Metastatic Melanoma**
- **09:00 - 11:00**
  - **Chair:** A. M. M. Eggermont (France)
  - **Co-Chair:** PA. Acocella (Italy)
  - **Introduction**
    - Speaker: S. A. W. Fuqua (USA)
  - **Biomarkers for the complex biology of melanoma immunotherapy**
    - Speaker: C. Robert (France)
  - **Immunogens and immunostimulatory monoclonal antibodies**
    - Speaker: M. Reck (Germany)
  - **Melanoma targeted therapies in the interface with immunotherapy**
    - Speaker: A. Abbas (USA)
  - **Virotherapy and immunotherapy**
    - Speaker: C. A. B. Fletcher (United Kingdom)
  - **Discussion & Roundup**

**Scientific Symposium: Personalised Medicine: Biomarkers, Surrogacy and Companion Diagnostics**
- **09:00 - 10:30**
  - **Chair:** R. Marius (United Kingdom)
  - **Co-Chair:** R. Tellan (Germany)
  - **How to optimise endocrine sequence in luminal breast cancer**
    - Speaker: S. A. W. Fuqua (USA)
  - **Genomics and response to endocrine therapies**
    - Speaker: M. Reck (Germany)
  - **Role of cyclin-dependent kinase 4/6 inhibitors in endocrine therapy**
    - Speaker: F. Cardoso (Portugal)

**Discussion & Roundup**
- **10:45 - 11:30**
  - **Chair:** F. Cardoso (Portugal)
  - **Panel:** A. Irrthum (Belgium)

**Special Session: Resistance in Patients with Oncogenic Alterations**
- **11:15 - 12:15**
  - **Chair:** D. R. Camidge (USA)
  - **Tumour cells heterogenetics evolution**
    - Speaker: C. Suwont (United Kingdom)
  - **Overcoming resistance in patients with KIT and PDGFR-A translocations**
    - Speaker: D. Cardoso (Portugal)
  - **Perspectives in management of EGFR resistance**
    - Speaker: S. A. W. Fuqua (USA)
  - **Discussion**

**Scientific Symposium: Immunotherapy in NSCLC - 2015**
- **09:00 - 10:30**
  - **Chair:** R. Pacini (Italy)
  - **Co-Chair:** D. Geisinger (Austria)
  - **Discussion & Roundup**

**Educational Symposium: What is the Optimal Endocrine Therapy in Premenopausal Women with Early Breast Cancer**
- **16:45 - 18:45**
  - **Chair:** T. Andre (France)
  - **What is the definition of an ER+ breast cancer?**
    - Speaker: P. Aus Illing (United Kingdom)
  - **Which endocrine therapy for the premenopausal woman with ER+/HER2+++ disease? Update on TERT and SOFT trials**
    - Speaker: V. Gym Embassy (Netherlands)
  - **Unusual molecular and clinical profiles: HER2±10%, ER+/PR+ and large tumours in premenopausal women**
    - Speaker: B. Beighl (Sweden)
Scientific Symposium: Therapeutic Implication of Intra Tumour Heterogeneity in Breast Cancer

17:00 - 18:30
Chair: A. Barennes-Dolé (Norway)
Co-Chair: C. Caldas (United Kingdom)
Inference of tumour evolution during chemotherapy
Speaker: J. Aparicio (Canada)
Heterogeneity and treatment failure in HER2 positive breast cancers
Speaker: C. Carey (USA)
Role of liquid vs solid biopsies in monitoring treatment
Speaker: C. Caldas (USA)
New frontiers in molecular imaging to improve targeting of high risk disease
Speaker: E.C. De Vries (Netherlands)

Discussion & Roundup

Monday 28 September 2015

Integrated Session: Novel Approaches to Brain Metastases

09:45 - 11:15
Chair: S. Gombi (Germany)
Co-Chair: A. Enzi (Romania)

Biography of brain metastases
Speaker: P. Stone (USA)
Novel systemic therapy approaches to brain metastases: Lung
Speaker: S. Popat (United Kingdom)
Novel systemic therapy approaches to brain metastases: Breast
Speaker: M. Prosser (Australia)
Novel systemic therapy approaches to brain metastases: Melanoma
Speaker: D. Schlabendorf (Germany)

Advances in loco-regional treatments
Speaker: M. Broida (United Kingdom)
Tolerance of brain metastasis treatments
Speaker: A. Soffietti (Italy)
Response assessment in brain metastases
Speaker: N. Lin (USA)

Discussion & Roundup

Society Session: European Society of Breast Cancer Specialists (EUSOMA)

09:15 - 11:15
Chair: M. Lladinteresting (Finland)
Chair: I. Pyrdal (United Kingdom)

Radiotherapy and DCIS
Speaker: B. Cuzick (United Kingdom)
What are the chemoprevention options for high risk women?
Speaker: J. Cuzick (United Kingdom)
Treating positive nodes in the axilla
Speaker: C. Marques (France)
How much oncoplastic surgery?
Speaker: A.R. Mansur (United Kingdom)
Should we tailor adjuvant therapy to specific sub-types?
Speaker: G. Ragni (Italy)
Genetic counselling for women with DCIS and positive family history
Speaker: R. Bonanni (Italy)

Discussion

Debate: This House Believes that Mammographic Screening Should Be Discontinued

11:30 - 12:30
Moderator: M. Rossiello del Sorbo (Italy)
Speaker e: favore: P. Zimbardi (Portugal)
Speaker anti: C. Carminati (Germany)
Seconda favore: G. Liefers (Netherlands)
Seconda anti: B. Bericht (Switzerland)

Discussion & Voting

Scientific Symposium: New Techniques in Avoiding Over-treatment in Early Breast Cancer

17:00 - 18:30
Chair: M. Llademolin (Finland)
Co-Chair: A. Loi (Italy)

Avoiding surgery in DCIS: How can we select low risk disease
Speaker: A. Francis (United Kingdom)
Minimising harm and maximising benefit with radiotherapy; New horizons
Speaker: C. Gile (United Kingdom)

Surgical strategies for gene carriers: Breast conservation versus unilateral or bilateral mastectomy
Speaker: G. Cangemi (Italy)
Adjuvant systemic therapy: Could it be less intensive?
Speaker: M.A. Colombo (Italy)
Tailoring chemotherapy for hereditary breast cancer carriers
Speaker: A. Tutt (United Kingdom)

Discussion

Tuesday 29 September 2015

Teaching Lecture: Staging the Axilla: Imaging and Sentinel Node Technologies

08:00 - 08:45
Chair: L. Kyle (United Kingdom)
Speaker: T. Rubio (Spain)

Scientific Symposium: Optimal Treatment of Luminal Breast Cancer: Emerging Data on Improving Response to Hormone Therapy

09:00 - 10:30
Chair: M. Colombo (Italy)
Co-Chair: S.A. Fizazi (USA)

How to optimise endocrine sequence in luminal breast cancer
Speaker: S.A. Fizazi (USA)
Introducing mTOR and PI3K inhibitors in endocrine therapy
Speaker: M. Martin (Spain)
Genomics and response to endocrine therapies
Speaker: M. Eto (USA)
Role of cyclin-dependent kinase 4/6 inhibitors in endocrine therapy
Speaker: F. Cardoso (Portugal)

Discussion & Roundup

Monday 28 September 2015

Special Session: Management Strategies for Hereditary Gene Mutation Carriers with Early Breast Cancer

17:15 - 18:15
Chair: P. Poortmans (Netherlands)

Co-Chair: C. Kenis (Belgium)

Assessing patients for treatment
Speaker: S. Rostoft (Norway)
Breast conservation versus unilateral or bilateral mastectomy
Speaker: I. Rahm Hallberg (Sweden)
Breast conservation versus unilateral or bilateral mastectomy
Speaker: G. Liefers (Netherlands)
Surgical strategies for gene carriers: Breast conservation versus unilateral or bilateral mastectomy
Speaker: G. Cangemi (Italy)
Adjuvant systemic therapy: Could it be less intensive?
Speaker: M.A. Colombo (Italy)
Tailoring chemotherapy for hereditary breast cancer carriers
Speaker: A. Tutt (United Kingdom)

Discussion

CANCER IN ELDERLY

Saturday 26 September 2015

Scientific Symposium: Managing Older People with Cancer and Other Co-Morbidities - An Increasing Challenge

17:45 - 18:15
Chair: M. Wells (United Kingdom)
Co-Chair: C. Sharpe (Saudia)

New models of follow-up for increasingly complex patient profiles
Speaker: C. Cattaneo (Italy)
Meeting complex care needs in the clinic. The example of polypharmacy
Speaker: F. Van den Broucke (Netherlands)
The importance of appropriate assessment for people with cancer
Speaker: C. Kiers (Belgium)
Being innovative to support older people with cancer in clinical settings
Speaker: J. Winkler (United Kingdom)
Selection for risk reduction surgery in hereditary syndromes
Speaker: A. Tutt (United Kingdom)

Discussion

Scientific Symposium: The Challenges of Treating the Older Patient with Upper GI Cancer

17:00 - 18:30
Chair: M. Arora (Switzerland)
Co-Chair: D. Papamichael (Cyprus)

Assessing patients for treatment
Speaker: S.W. Rostaff (Norway)
The oncologist’s perspective
Speaker: S.A. Balmont (Germany)
Are you ever too old for complex upper GI surgery?
Speaker: W. Allum (United Kingdom)
A radiotherapist perspective
Speaker: A. G. Morganti (Italy)

Discussion & Roundup


**Tuesday 29 September 2015**

Special Session: Clinical Challenges in Adjunct Therapy in Rectal and Colon Cancer
- 11:15 - 12:15
  - Chair: A. Carton (Spain)

Adjuvant therapy in rectal cancer
Speaker: K. Hautmann (Belgium)

Adjuvant therapy in the elderly
Speaker: D. Papaspyrakis (Greece)

Adjuvant therapy in stage II colon cancer
Speaker: J. Tesse (France)

Discussion

**CANCER PREVENTION AND SCREENING**

**Sunday 27 September 2015**

Special Session: HPV Vaccine for Cancer Prevention
- 11:30 - 13:15
  - Chair: K. Soldan (United Kingdom)

Achieving high coverage of HPV vaccination
Speaker: K. Bosch (Spain)

Vaccination of boys/young males
Speaker: R. Herrero (France)

Precinclinical vaccines
Speaker: C.J.M. Melief (Netherlands)

Discussion

Central Nervous System

**Saturday 26 September 2015**

Society Session: European Association of Neuro-Oncology (EANO) - New Tools and Toys in Neuro-Oncology
- 10:30 - 12:30
  - Chair: M. Harvie (United Kingdom)

Exercise and cancer – mechanisms and interventions
Speaker: C. Ulrich (Germany)

How acceptable is exercise intervention to cancer patients
Speaker: C. Watts (United Kingdom)

Body weight, exercise and colorectal cancer screening
Speaker: A. Anderson (United Kingdom)

Discussion

**Monday 28 September 2015**

Teaching Lecture: Antiangiogenic Therapies in Neuro-Oncology: Current State of Development
- 08:00 - 08:45
  - Chair: C. Watts (United Kingdom)

The importance of extent of resection
Speaker: J. Taieb (France)

Does an optimal chemotherapy treatment exist in adults?
Speaker: R. Herrero (Italy)

Radiotherapy techniques and indications for the treatment of low grade gliomas
Speaker: R. Stupp (Switzerland)

Discussion

**Clinical Trials and Regulatory Affairs**

**Saturday 26 September 2015**

Society Session: European Society of Oncology Pharmacy (ESOP)
- 16:45 - 18:15
  - Chair: K. Meier (Germany)

ESOP-ESMO Drug shortage survey
Speaker: M. Vour (Estonia)

EPIC project on oral chemotherapy
Speaker: A. Ten (Ireland)

Pharmacist involvement in Slovenia
Speaker: M. Tev (Ireland)

Cytotoxic contamination project
Speaker: K. Kozak (Ireland)

Centres of exchange
Speaker: C. Bardet (France)

Klaus Meier Award

**Sunday 27 September 2015**

Special Session: How to Pay for New “Innovative” Anti-cancer Drugs?
- 11:30 - 12:30
  - Chair: A. Astier (France)

A new way to pay high costly drugs:
Payment for the performances
Speaker: F. Megerlin (France)

Does the claims of “innovation” of new anticancer drugs justify their too high costs?
Speaker: J. Taieb (France)

Cost constraints in cancer treatment:
What can nations do?
Speaker: C. Watts (United Kingdom)

Discussion
**Monday 28 September 2015**

**Special Session: The Quality of Reporting Clinical Trials**
- **12:30 - 12:45**
  - Chair: C. Djité (Austria)
  - Why the reported results of clinical trials are often false

**Special Session: Evaluating Clinical Benefit of Cancer Drugs across Tumours**
- **12:45 - 13:05**
  - Chair: J.G.E. de Bries (Netherlands)
  - Clinical benefit scale: The European proposal

**Special Session: The Global Impact of the EU Paediatric Regulation across All Ages**
- **13:15 - 13:30**
  - Chair: F. Kamins (United Kingdom)

**Special Session: Personalised Medicine: Biomarkers, Surrogacy and Companion Diagnostics**
- **17:00 - 18:30**
  - Chair: S. Lecuit (Belgium)
  - Pharmacologic biomarkers in the development of stratified cancer medicine
  - One size doesn’t fit all - current status of commonly used surrogate markers across tumours: Paradigms from colorectal, lung and breast cancer

**Scientific Symposium: Bayesian, Adaptive and Rare Disease Designs**
- **09:00 - 10:30**
  - Chair: U. Dafni (Greece)
  - Design in rare disease: The oncologist perspective

**Scientific Symposium: New Drugs on the Horizon I**
- **09:15 - 10:45**
  - Chair: J.M. Schlenk (Netherlands)
  - Malanoma: Immunotherapy, TKIs, chemotherapy, combinations? What’s next?

**Scientific Symposium: New Drugs on the Horizon II**
- **09:15 - 10:45**
  - Chair: F. Raymond (Switzerland)
  - TNBC: Biomarkers and opportunities for individualised therapy

**Scientific Symposium: New Insights in Colorectal Cancer**
- **16:45 - 18:15**
  - Chair: D. Auri (Germany)
  - Biomarkers to guide therapy today, what to assess and how

**Debate: This House Believes that Single Agent Activity is Required for Development in Combination Therapy**
- **15:15 - 16:15**
  - Moderator: R. Salazar (Spain)
  - Speaker in favour: T. Yap (United Kingdom)
  - Speaker against: J.M. Schlenk (Netherlands)
  - Seconder in favour: C. Marijnen (Netherlands)
  - Seconder against: A. Martling (Sweden)

**Teaching Lecture: Use of the Preoperative Window for Early Drug Development**
- **08:00 - 08:45**
  - Chair: R. Plummer (United Kingdom)

**Debate: This House Believes that Supplementary Rectal Irradiation Can Avoid Surgery and Achieve more Complete Clinical Remission**
- **11:30 - 12:30**
  - Moderator: R. Salazar (Spain)
  - Speaker in favour: C. Rolland (Germany)
  - Speaker against: J.M. Schlenk (Netherlands)
  - Seconder in favour: C. Marijnen (Netherlands)
  - Seconder against: A. Martling (Sweden)
GASTROINTESTINAL MALIGNANCES - NONCOLORECTAL CANCER

Monday 28 September 2015

Scientific Symposium: The Challenges of Treating the Older Patient with Upper GI Cancer

17:00 - 18:30
Chair: M. Alpert (Switzerland)
Co-Chair: D. Papamichael (Cyprus)

Assessing patients for treatment: Speaker: J.A. Rahal (Norway)
The oncologist’s perspective: Speaker: S. Al-Boos (Cameroon)
Are you ever too old for complex upper GI surgery?: Speaker: V. Alum (United Kingdom)
A radiotherapist perspective: Speaker: A. Morgan (Italy)

Discussion & Roundup

GASTROINTESTINAL MALIGNANCES - NONCOLORECTAL CANCER

Monday 28 September 2015

Special Session: The Molecular and Histological Classification of Gastro-Eosophageal Cancer: Implications for Treatment

11:30 - 12:30
Chair: M. Halas (Spain)

Re-classification of OG cancer through distinct molecular phenotypes: Speaker: A. Bass (USA)

Implication for therapeutic exploitation: Speaker: D. Cunningham (United Kingdom)

Tailored surgical approach: Speaker: V. Valention (Italy)

Discussion

Debate: This House Believes that Neoadjuvant Therapy is a Promising Treatment in Resectable Pancreatic Cancer

13:15 - 14:15
Moderator: J. Soubidou (Greece)
Speaker in favour: S. Al-Boos (Cameroon)
Speaker against: M. Ramades (France)
Seconded by: S. Gagnon (Canada)
Seconded against: B. Slavin (United Kingdom)

Discussion & Voting

Scientific Symposium: Muscle Invasive Bladder Cancer

17:00 - 18:30
Chair: T. De Rooye (Netherlands)
Co-Chair: C.N. Sternberg (Italy)

Scientific Symposium: The Role of Radiotherapy in Locally Advanced Rectal Cancer

09:00 - 11:30
Chair: J. Druart (France)

Hazards of radical cystectomy in the elderly: Speaker: M. Brausi (Italy)
Carboplatin based chemotherapy: Speaker: M. De Santis (Australia)
Reducing the toxicity of radiotherapy: Speaker: A. Mudd (United Kingdom)
Combined modality treatment put into context for practice: Speaker: J. Druart (France)

Discussion & Roundup

GENITOURINARY MALIGNANCES - NON PROSTATE

Sunday 27 September 2015

Teaching Lecture: New Targets in Renal Cell Carcinoma: What Can We Expect for the Future?

08:00 - 08:45
Chair: C.N. Sternberg (Italy)
Speaker: B. Escudier (France)

Scientific Symposium: Muscle Invasive Bladder Cancer

17:00 - 18:30
Chair: T. De Rooye (Netherlands)
Co-Chair: C.N. Sternberg (Italy)

Biomarkers in bladder cancer: Speaker: T. Bellmunt (USA)
Surgical treatments: What is new?: Speaker: T. Labot (France)
Chemoradiotherapy: Speaker: H.J. James (United Kingdom)
Neo-adjuvant versus adjuvant treatment: Speaker: C.N. Sternberg (Italy)

Discussion & Roundup

Monday 28 September 2015

Educational Symposium: Combined Modality Treatment in Elderly with Bladder Cancer

09:00 - 11:30
Chair: J. Druart (France)

Hazards of radical cystectomy in the elderly: Speaker: M. Brausi (Italy)
Carboplatin based chemotherapy: Speaker: M. De Santis (Australia)
Reducing the toxicity of radiotherapy: Speaker: A. Mudd (United Kingdom)
Combined modality treatment put into context for practice: Speaker: J. Druart (France)

Discussion & Roundup

Debate: This House Believes that All Patients with Stage I Testicular Cancer (Seminoma and Non-Seminoma) Should Go on Active Surveillance

13:15 - 14:15
Moderator: S. Gilchrist (Switzerland)
Speaker in favour: C. Altmanninger (Canada)
Speaker against: J. Beyer (Switzerland)
Seconded by: S. Gagnon (Canada)
Seconded against: J. Aparicio Urtasun (Spain)

Discussion & Voting

Tuesday 29 September 2015

Scientific Symposium: Prognostic Factors in Different Areas of Prostate Cancer

11:45 - 12:15
Chair: B. Escudier (France)

Basic science of immunotherapy: Speaker: C. Drake (USA)
Immunotherapy in renal cancer: Speaker: T. Phauk (United Kingdom)
Immunotherapy in genitourinary cancer: Speaker: W.R. Gerritsen (Netherlands)

Discussion
Monday 28 September 2015

Gynaecological Cancer

Teaching Lecture: Image Guided Dose and Volume Adaptation in Cervix Cancer
- 08:00 - 08:45
  Chair: P. Neven (United Kingdom)
  Speaker: R. Pitter (Belgium)

Special Session: New Trends in Cervical Cancer Chemotherapy and Radiation Oncology
- 11:30 - 12:30
  Chair: A. Roscioni (Spain)
  Novel Systemic treatments and immunotherapy - how to combine
  Speaker: P. Uc (Italy)
  IMRT: Stargate to more intense chemotherapy schedules?
  Speaker: A. Kopp (USA)
  Late toxicity and quality of life results
  Speaker: P. Neven (United Kingdom)

Special Session: Cancer in Pregnancy
- 15:30 - 16:15
  Chair: D.A. Cameron (United Kingdom)
  Breast cancer in pregnancy
  Speaker: S. Lahoti (Germany)
  Gynaecological cancer in pregnancy
  Speaker: R. Fruscio (Italy)
  The obstetrical, perinatal and pediatric point of view
  Speaker: F. Amant (Belgium)

Treatement of Uterine Cancer in the octogenarians
  Speaker: M. Clarke (United Kingdom)

Discussion & Roundup
Tuesday 29 September 2015

Society Session: European Association of Urology (EAU) - Uterine Cancer in 2015
- 09:00 - 11:00
  Chair: A. Steck (Germany)
  Risk stratification of uterine cancer in the lower and upper urinary tract
  Speaker: S. Shariat (Austria)
  Matula Award Lecture: Biomarkers in uterine cancer: When and where to use
  Speaker: M. Rojas (France)
  Does minimisation of surgery improve the outcome of cytostomy for uterine cancer?
  Speaker: P. Vlhova (Slovakia)

Treatment of Uterine Cancer in the octogenarians
  Speaker: M. Clarke (United Kingdom)

Scientific Symposium: Biology Based Selected Drugs in Ovarian Cancer Treatment
- 17:00 - 18:30
  Chair: R. Guazzato (Italy)
  Co-Chair: I.B. Vergote (Belgium)
  Drug acting on ovarian cancer cells and tumour microenvironment
  Speaker: M. D'Incalci (Italy)
  Folate receptor blockers
  Speaker: I.B. Vergote (Belgium)
  Treatment opportunities for homologous recombinant deficiency (PARP) inhibitors
  Speaker: S. Benencia (United Kingdom)
  Immunotherapy opportunities in ovarian cancer
  Speaker: C. Cividolo (Switzerland)

Discussion & Roundup

Tuesday 29 September 2015

Teaching Lecture: Laparoscopic and Robotic Surgery in the Treatment of Gynaecological Malignancy
- 08:00 - 08:45
  Chair: G. Ferrandina (Italy)
  Speaker: C. Scambia (Italy)
  Debate: This House Believes that Ovarian Platinum-Sensitive Carcinoma in Relapse Needs Platinum Based Chemotherapy
- 12:15 - 12:45
  Moderator: I. Ray-Coquard (France)
  Speaker: S. Ludovica (Italy)
  First line treatment
  Speaker: T.R. Robak (Poland)
  Treatment for relapse/refractory disease
  Speaker: P. Vici (Italy)
Special Session: Genetic Traits for Myeloid Malignancies
21:30 - 12:30 Chair: J. Story (Czech Republic)

Current concepts for familial AML
Speaker: J. Figl (United Kingdom)

GATA deficiencies
Speaker: M. Wodarz (Germany)

Genetic counselling
Speaker: R. Schlegelberger (Germany)

Discussion

Tuesday 29 September 2015

Teaching Lecture: The Spectrum of Cutaneous Lymphomas: From Molecular Biology to Therapy
08:00 - 08:45
Chair: M. Federico (Italy)
Speaker: R. Bernier (Switzerland)

Debate: This House Believes that We Should Treat First Line Advanced Follicular Lymphoma without Chemotherapy
21:15 - 12:15
Moderator: A. Lister (United Kingdom)
Speaker in favour: M. Federico (Italy)
Speaker against: W. Predmann (Germany)

Discussion

HEAD AND NECK CANCER
Saturday 26 September 2015

Teaching Lecture: Dose Escalation or De-Escalation in Head and Neck Cancer?
07:45 - 08:30
Chair: D. Zips (Germany)
Speaker: V. Gregoire (Belgium)

Debate: This House Believes that Concurrent Chemotherapy Combined with Hyperfractionated Radiotherapy Should Be the Current Standard in HPV Negative Locally Advanced Head and Neck Cancer
21:15 - 16:15
Moderator: A. Pyy (Finland)
Speaker in favour: P. Blanchard (France)
Speaker against: J.C. Ehrlich (Denmark)
Second in favour: W. Budach (Germany)
Second in favour: M. Merlato (Italy)

Discussion

IMAGING
Saturday 26 September 2015

Special Session: Minimally Elevated PSA after Prostatectomy: Hold Your Horses or All Hands on Deck?
11:15 - 16:15
Chair: W.C. Oyen (Netherlands)

Role of advanced MRI for detection of minimal disease
Speaker: H.C. Vlietinck (Switzerland)

Role of PSMA-PET/CT for detection of minimal disease
Speaker: B.J. Krause (Austria)

All hands on deck: Early image-guided high-precision treatment
Speaker: F. van Herle (United Kingdom)

Hold your horses: Wait and see, do not over treat
Speaker: P. Abrahamsson (Sweden)

Discussion

SUNDAY 27 SEPTEMBER 2015

Multidisciplinary Tumour Board: Locally Advanced Disease
11:30 - 12:30
Chair: J. Machiels (Belgium)

Case presentation by young oncologist: Advanced disease
Speaker: I. Vansteenkiste (Belgium)

Panel Discussion: Advanced disease

Pathologist
Panel: H.C. Vlietinck (Switzerland)

Medical Oncologist
Panel: P. Valdés Olmos (Portugal)

Surgical Oncologist
Panel: J. Bubendorf (Switzerland)

Pathologist
Panel: F. Feve (Belgium)

Oncology Nurse
Panel: I. Kerkhofs (Belgium)

Discussion

Special Session: Strategies to Change the Therapeutic Landscape of Head and Neck Cancer
12:30 - 12:45
Chair: M. Machiels (Belgium)

Consequences of new imaging techniques in treatment of the neck
Speaker: V. Gregoire (Belgium)

Case presentation by young oncologist: Locally advanced disease
Speaker: R. Callegaro (Belgium)

Panel Discussion: Locally advanced disease

Special Session: Genetic Malignancies - Prostate Cancer
15:15 - 16:15
Chair: B. Escudier (France)

Case presentation by young oncologist: Early disease
Speaker: G. Campone (France)

Panel Discussion: Early disease

Radiation Oncologist
Panel: J.A. Roobol (Netherlands)

Surgical Oncologist
Panel: P. Valdés Olmos (Portugal)

Pathologist
Panel: E. Baramski (France)

Radiologist
Panel: J. Coello (Belgium)

Oncology Nurse
Panel: K. Cedermark (Sweden)

Discussion

Case presentation by young oncologist: Advanced disease
Speaker: M.A. Ozturk (Turkey)

Panel Discussion: Advanced disease

Urologist
Panel: F. De Boeck (Netherlands)

Radiologist
Panel: J. Vansteenkiste (Belgium)

Pathologist
Panel: J. Van der Vorst (Netherlands)

Debate: This House Believes that Mammographic Screening Should Be Discontinued
11:30 - 12:10
Moderator: M. Rossi (Italy)
Speaker in favour: P. Zorzoli (Norway)
Speaker against: G.A. Cameron (United Kingdom)
Second in favour: G. Lieber (Netherlands)
Second in favour: B. Borsch (Switzerland)

Discussion
IMMUNOTHERAPY OF CANCER

SATURDAY 26 SEPTEMBER 2015

Scientific Symposium: Cellular Immunotherapy of Cancer

10:30 - 12:00
Chair: A.J. Noone (United Kingdom)
Co-Chair: I. Melero (Spain)

Introduction
Speaker: A.J. Noone (United Kingdom)

By imaging
Speaker: S. Koch (Germany)

By combining Immunotherapy and Anti-VEGF therapy
Speaker: G. Coukos (Switzerland)

By supporting decision tools
Speaker: P. Hwu (United States)

Is cancer immunosurveillance relevant?
Speaker: J. Galon (France)

Discussion & Roundup

Tuesday 29 September 2015

Teaching Lecture: Staging the Axilla: Imaging and Sentinel Node Technologies

08:00 - 08:45
Chair: L. Wyld (United Kingdom)
Speaker: V. Galisteo (Spain)

Teaching Lecture: Rectal Cancer and the Role of Imaging in Treatment Planning

08:00 - 08:45
Chair: V. Galisteo (Spain)
Speaker: C. Bents (Netherlands)

IMMUNOTHERAPY OF CANCER

Sunday 27 September 2015

Educational Symposium: Advances in Cancer Therapy Through Modulation of the Immune System

12:45 - 14:00
Chair: A. M. M. Eggermont (France)
Co-Chair: L. Voci (Italy)

Introduction
Speaker: A. M. M. Eggermont (France)

Biomarkers for complex biology of melanoma immunotherapy
Speaker: S. Behr (Germany)

Immunogens and immunostimulatory monoclonal antibodies
Speaker: M. Shen (Spain)

Melanoma targeted therapies in the interface with immunotherapy
Speaker: M. Driver (USA)

Virotherapy and Immunotherapy
Speaker: A. Melcher (United Kingdom)

Discussion & Roundup

INNOVATIONS IN RADIATION ONCOLOGY

Saturday 26 September 2015

Scientific Symposium: New Trends in Molecular Targeting for Radiation Oncology

16:45 - 18:15
Chair: Y. Shiloh (Israel)
Co-Chair: T. Helleday (Sweden)

Radiotherapy, immunotherapy and virotherapy riddles
Speaker: P. Hwu (United States)

Learning radiimmunotherapy
Speaker: P. Rechsteiner (Germany)

Discussion

Sunday 27 September 2015

Teaching Lecture: Technical Innovations in Radiotherapy

08:00 - 08:45
Chair: D. van der Meulen (Belgium)
Speaker: C. Krause (Denmark)

Special Session: Translating Innovations in Functional Imaging into Clinical Trials

11:30 - 12:30
Chair: Y. Galon (France)

Biological and clinical rationale of the use of functional imaging
Speaker: R. Byun (Korea)

How to apply functional imaging in the radiation oncology clinic
Speaker: M. Dosemeci (Denmark)

From image to dose prescription and back
Speaker: W. Van Elsingen (Netherlands)

Discussion

Special Session: Think Big: Larga Databases for Research in Radiation Oncology

15:45 - 16:45
Chair: M. A. Reamon (Germany)

Big databases and outcome research: Opportunities and challenges for radiation oncology
Speaker: A. Hutter (Netherlands)

Radion Rice: Database for individualized radiation oncology
Speaker: M. Krause (Germany)

The breast cancer example: Lesson from large databases
Speaker: B. L. Hoff (Denmark)

Discussion
ECCO 18 – ESMO 40 - European Cancer Congress - ADVANCE PROGRAMME

Educational Symposium: Radiation Combined with Targeted Agents- The Example of Head and Neck Cancer
- 08:45 - 10:45
Chair: M. Krause (Germany)
Principles and theory behind
Speaker: M. Krause (Germany)
The clinical outcome
Speaker: L. Licitra (Italy)
How to manage toxicity
Speaker: E. Deutsch (France)
The HPV story
Speaker: J. C. Eriksen (Denmark)
Discussion & Roundup

Monday 28 September 2015

Society Session: European Society for Radiotherapy & Oncology (ESTRO)
- 09:15 - 11:15
Chair: P. Postma (Netherlands)
Regaud Award Lecture: Minimal effective treatments in the personalised era: The breast model
Award lecturer: R. Grechka (Italy)
ESTRO Honorary Members Award Lectures
Title to be announced
Award lecturers: A. L. Zietman (USA)
Title to be announced
Award lecturer: A. Cervantes (Spain)
Company Award Lectures
Accuracy Award
Award lecturer: To be announced
Variasion Award
Award lecturer: To be announced

Debate: This House Believes that Local Radiation Therapy Also Has Therapeutic Effects Outside the Radiation Fields and thereby Contributes to Treatment Outcome
- 11:30 - 12:30
Moderators: M. Verha (Netherlands)
Speaker in favour: T. Vena (Germany)
Speaker against: B. Offring (Denmark)
Second in favour: S. C. Mergen (Canada)
Second against: D. Verbeeck (Germany)
Discussion & Voting

Special Session: How to Use Omics Data for Precision Radiation Oncology
- 12:15 - 14:45
Chair: D. Zips (Germany)
How to bring “radio-omics” and functional tests in the clinic
Speaker: S. Wouters (Canada)
Systems biology for precision radiation oncology: Moving between the forest and the trees
Speaker: Y. Zhih (Israel)
Clinical Results: Can we cure oligometastatic disease?
Speaker: M. Hoyer (Germany)
How to manage target motion during treatment?
Speaker: M. Guckenberger (Germany)
Discussion

LUNG CANCER - LOCALISED/LOCAL REGIONAL AND METASTATIC
Saturday 26 September 2015
Teaching Lecture: Personalised Radiotherapy: Dream or Reality?
- 08:00 - 08:45
Chair: P. Postma (Netherlands)
Speaker: M. Baum (Germany)
Scientific Symposium: High-Tech Innovations for Precision Radiation Oncology: Concept, Status and Clinical Benefit
- 09:00 - 10:30
Chair: P. Postma (Netherlands)
Co-Chair: D. Geir (Austria)
How can protons contribute to radiation oncology
Speaker: M. Szczyrba (Italy)

Special Session: Lung Cancer Screening and Prevention
- 14:15 - 16:15
Chair: W. Weder (Switzerland)
Lung cancer prevention and smoking cessation
Speaker: To be announced
Lung cancer screening: Ready for standard of care in Europe?
Speaker: C. Vencetti (Italy)
Discussion

Educational Symposium: Profiling Lung Cancer – Collection of Rare Cancers
- 14:45 - 16:45
Chair: F. Cellini (Italy)
Targets in squamous cell carcinoma
Speaker: R. Besc (France)
Targets in adenocarcinoma
Speaker: J. C. Soria (France)
Targets in SCLC
Speaker: M. C. Pietanza (USA)
Upfront biomarker analysis to guide stage VI treatment: Practical use
Speaker: S. Pileri (Switzerland)
Discussion & Roundup

Sunday 27 September 2015
Multidisciplinary Tumour Board: Lung Cancer
- 11:30 - 12:30
Chair: J. Vantstenhove (Belgium)
Case presentation by young oncologist: Early disease
Speaker: F. Collins (Italy)
Panel Discussion: Early disease
Case presentation by young oncologist: Locally advanced disease
Speaker: A. Lagrins (France)
Panel Discussion: Locally advanced disease
Case presentation by young oncologist: Advanced disease
Speaker: A. Calvery (United Kingdom)
Panel Discussion: Advanced disease
Radiation Oncologist
Panel: J. A. Bledova (Netherlands)
Surgical Oncologist
Panel: J. Edwards (United Kingdom)
Pathologist
Panel: E. Brambilla (France)
Radiologist
Panel: J. C. Soares (Belgium)
Oncology Nurse
Panel: K. Colenbrander (Sweden)
Scientific Symposium: Innovations Broadening the Horizon for Locally Advanced Non-Small Cell Lung Cancer
- 17:00 - 18:30
Chair: Y. Lejeans (Belgium)
Co-Chair: B. Bese (France)
New insights in tumour biology
Speaker: S. R. A. A. (Switzerland)
Minimally invasive surgery for locally advanced tumours
Speaker: M. Sykowsky (USA)
Novel radiotherapy technology improving the therapeutic index
Speaker: J. A. Bledova (Netherlands)
(Neoadjuvant treatment: Which way to go?
Speaker: B. Bese (France)
Discussion & Roundup

Monday 28 September 2015
Teaching Lecture: Targeted Therapies for Adenocarcinoma of the Lung
- 08:00 - 08:45
Chair: J. S. A. Belderbos (Netherlands)
Speaker: F. Cellini (Italy)
Integrated Session: Novel Approaches to Brain Metastases
- 09:15 - 11:15
Chair: J. S. A. Belderbos (Netherlands)
Co-Chair: J. E. Eniu (Romania)
Biology of brain metastases
Speaker: P. Stoj (Italy)
Novel systemic therapy approaches to brain metastases: Lung
Speaker: S. Popat (United Kingdom)
Novel systemic therapy approaches to brain metastases: Breast
Speaker: M. Preusser (Australia)
Novel systemic therapy approaches to brain metastases: Melanoma
Speaker: D. Schadendorf (Germany)
Advances in loco-regional treatments
Speaker: M. Baida (United Kingdom)
Tolerability of brain metastasis treatments
Speaker: R. Tacchetti (Italy)
Response assessment in brain metastases
Speaker: A. L. Zietman (USA)
Discussion & Roundup

Debate: This House Believes that Surgery Remains the Gold Standard for Early Stage NSCLC
- 11:30 - 12:30
Moderator: G. Veronesi (Italy)
Speaker in favour: W. Weder (Switzerland)
Speaker against: U. Ricardi (Italy)
Second in favour: S. Nanni (Italy)
Second against: V. Surmont (Belgium)
Discussion & Voting
SUNDAY 27 SEPTEMBER 2015

Special Session: Living with and Beyond Cancer
- 12:30 - 12:30
Chair: E. Van Mullem (Netherlands)

The benefits of physical activity during and following cancer treatment: The patient perspective
Speaker: N. House (United Kingdom)

Living with cancer risk: Supporting patients and families with examples from breast cancer
Speaker: D. Rozu (Belgium)

Beyond cancer: The fear of cancer recurrence
Speaker: C. Gokalp (United Kingdom)

Discussion

Special Session: Nutrition and Body Image Changes - A Concern for All Patients with Cancer
- 13:15 - 16:15
Chair: M. Lacerda (Portugal)

Weight gain during cancer therapy: Issues for cancer practice
Speaker: Y. Vergnion (Switzerland)

Swallowing difficulties: Lessons from head and neck cancer
Speaker: M. Wells (United Kingdom)

Cancer cachexia: What can we do to help?
Speaker: F. Storrer (Switzerland)

Discussion

Scientific Symposium: The Changing Face of Cancer Care for Oncology Nurses: The Rising Demand Being Placed on Cancer Services
- 17:00 - 18:30
Chair: M. Lacerda (Portugal)
Co-Chair: K. Laker (Slovenia)

Meeting the support needs of patients, carers & families after cancer treatment
Speaker: C. Foster (United Kingdom)

Factors underlying workplace stress: Lessons for cancer nursing
Speaker: A. Caruso (Italy)

Multi-disciplinary rehabilitation in advanced bladder cancer
Speaker: B. Thoft Jensen (Denmark)

Reducing emergency cancer admissions: A case study
Speaker: C. Bailey (United Kingdom)

Discussion & Roundup

ONCOPOLICY

SUNDAY 27 SEPTEMBER 2015

Oncopolicy Forum: Timebombs in Oncology: Cancer in the Elderly
- 13:00 - 14:30
Chair: B.A. Austin (United Kingdom)

With the retirement age increasing in many countries, the number of people working with long-term medical conditions including certain cancers will also increase. Some employers have recognised this and are implementing workplace initiatives to address the problem. This session will seek to provide policy solutions for the timebomb of cancer in the elderly.

Monday 28 September 2015

Oncopolicy Forum: EU Funding Opportunities for You and Your Team
- 11:30 - 12:30
Chair: A. Costa (Italy)

This session will unlock the possibilities for cancer research funding under the EU budget 2014-2020. It will enable participants to understand the sometimes complex landscape and identify the most relevant opportunities to benefit from available programmes, such as Horizon 2020.

Oncopolicy Forum: Timebombs in Oncology: The Oncology Workforce
- 13:00 - 14:30
Chair: To be announced

This session will consist of a multidisciplinary cancer panel giving their perspectives on the timebomb that is the oncology workforce. Discussion with the audience will seek to solicit possible policy solutions in anticipation of workforce shortages in essential disciplines.

Oncopolicy Forum: Tackling Rare Cancers Requiring Specialist Care: European Reference Networks
- 17:00 - 18:30
Chair: P. Cassi (Italy)

This session will address the cross-border movement of cancer patients and the setting up of European Reference Networks. Patients and the rare cancers community will provide their perspectives on this development.

Special Session: Precision Medicine and New Drugs for the Treatment of Children and Adolescents with Cancer
- 15:15 - 16:15
Chair: G. Vassal (France)

Tumour molecular profiling to guide new drug development: Experiences from Germany, France, UK and Netherlands
Speaker: S. Pfister (Germany)

Is B-RAF and MEK pathway relevant in paediatric malignancies?
Speaker: G. Geeargen (France)

Monoclonal antibodies in paediatric acute leukemias
Speaker: A. von Stackelberg (Germany)

Discussion & Roundup

Sunday 27 September 2015

Integrated Session: Treating Lymphoid Malignancies in Children and Adults with the Same Protocols
- 09:15 - 11:15
Chair: M. Psarras (Germany)
Co-Chair: G. Mann (Austria)

Introduction
Speaker: M. Psarras (Germany)

Burkit’s lymphoma in children
Speaker: V. Minard-Cosset (France)

Burkit’s lymphoma in adults
Speaker: L. Trumper (Germany)

Lymphoblastic leukaemia in children
Speaker: M. Hofman (Switzerland)

Lymphoblastic leukaemia in adults
Speaker: N. Bosilj (France)

Discussion & Roundup

Debate: This House Believes That Proton and Particle Therapy is Standard Treatment for Paediatric Malignancies
- 13:30 - 15:15
Moderator: K. Pritchard-Jones (United Kingdom)

Lymphoid Malignancies
Speaker: R. Ladenstein (Austria)

Integrate Session: Teenage and Young Adult Oncology
- 16:45 - 18:45
Chair: R. Ladesten (Austria)
Co-Chair: S. Balbuz (Germany)

Introduction
Speaker: R. Ladesten (Austria)

Improving access to clinical trials
Speaker: R. Garpar (France)

EU Curriculum
Speaker: O. Stark (United Kingdom)

Treatment and care of teenagers and young adults with a germ cell tumour
Speaker: G. Calaminus (Germany)
TUESDAY 29 SEPTEMBER 2015

Educational Symposium: Common Approaches & Pathways in Adult and Paediatric Malignancies

09:00 - 11:00

A. Pearson (United Kingdom)

Lessons and perspective in the treatment of high-risk neuroblastoma: The SIOPEN strategy

Speaker: D. Vallinon-Couvreur (France)

Strategies for improving maintenance therapy in high-risk neuroblastoma patients

Speaker: R. Laidenstien (Australia)

Introducing ALK inhibition therapy in neuroblastoma treatment

Speaker: A. Egger (Germany)

Targeting osteosarcoma: What is different between adult and paediatric patients?

Speaker: S. Beuckel (Germany)

Robust endpoints when evaluating novel “targeted” therapies

Speaker: M. Valsecchi (Italy)

Discussion & Roundup

PATHOLOGY

Saturday 26 September 2015

Teaching Lecture: Use of Liquid Biopsies

07:45 - 08:30

C. Cabezas (United Kingdom)

Current concepts and future directions in pharmacotherapy of medulloblastoma

Speaker: S. Pfister (France)

Molecular classification of medulloblastoma

Speaker: S. Pfister (France)

Recent results and current concepts for risk adapted medulloblastoma treatment: Experiences from the German HIT-studies and the SIOPEN-Europe PNET working group

Speaker: S. Rubben (Germany)

Restructuring efficiency and limiting toxicity of radiotherapy for medulloblastoma

Speaker: S. Combs (Germany)

Management of adult medulloblastoma - using the evidence from children and adolescents

Speaker: A. Brando (Italy)

Discussion & Roundup

Unusual molecular and clinical profiles: ERα-s+10%, ERβ-+ and large tumours in premenopausal women

Speaker: J. Bergh (Sweden)

Pregnancy and adjuvant endocrine therapy: Is there any window for opportunity?

Speaker: S. Joki (Germany)

Discussion & Roundup

Scientific Symposium: New Insights in Colon Cancer

20:45 - 18:15

D. Aust (Germany)

Predictive factors in radiotherapy induced toxicity

Speaker: Z. Dearnaley (United Kingdom)

Detection of predictive biomarkers in prostate cancer with novel molecular tools

Speaker: T. Van Der Kwast (Canada)

Predictive factors for treatment choice in metastatic castration resistant prostate cancer

Speaker: M. Scher (USA)

Discussion & Roundup

Scientific Symposium: Emerging Developments and Treatment Strategies in HPV Positive Head and Neck Cancer

20:45 - 18:15

L. Cicolisi (Italy)

What is the optimal Endocrine Therapy in Premenopausal Women with Early Breast Cancer?

Speaker: T. Andal (France)

Discussion & Roundup

Scientific Symposium: Predictive Factors in Different Areas of Prostate Cancer

20:45 - 18:15

R. Cathomas (Switzerland)

How to distinguish between significant and insignificant localised prostate cancer

Speaker: A. Bjartell (Sweden)

Predictive factors in radiotherapy induced toxicity

Speaker: Z. Dearnaley (United Kingdom)

Detection of predictive biomarkers in prostate cancer with novel molecular tools

Speaker: T. Van Der Kwast (Canada)

Predictive factors for treatment choice in metastatic castration resistant prostate cancer

Speaker: M. Scher (USA)

Discussion & Roundup

Scientific Symposium: Nooadjuvant Treatment - When Is it of Benefit for the Patient and Doctor?

20:45 - 18:15

R. A. Audius (United Kingdom)

Deintensification strategies in HPV-related head and neck cancer: Is there any role?

Speaker: R. Glynne-Jones (United Kingdom)

What does complete response look like?

Speaker: R. Glynne-Jones (United Kingdom)

The timing of radiotherapy in the NT setting

Speaker: J. S.J. Bos (France)

Pathological CR: Predicament or promise?

Speaker: A. P. De To (Italy)

Discussion & Roundup

Scientific Symposium: Cancer Genetics for Oncologists - Issues in Clinical Practice

16:45 - 18:15

S. Pastel-Knap (Italy)

Co-Chair: J. Reis-Filho (United Kingdom)

Germ line genetic testing for cancer patients

Speaker: To be announced

Implementation of widespread BRCA testing - the oncologist’s perspective

Speaker: S. Banerjee (United Kingdom)

Molecular profiling of cancers - clinical utility and limitations

Speaker: N. Normanno (Italy)

What do cancer patients understand about genetic testing?

Speaker: G. Casalari (Italy)

Discussion & Roundup

Scientific Symposium: Impact of Multi-drug Resistance - New Opportunities for Cancer Therapy

16:45 - 18:15

J. F. Bosset (France)

Targeting ERα in breast cancer - new insights

Speaker: K. Pritchard-Jones (United Kingdom)

Targeting HER2 in breast cancer - new insights

Speaker: P. Lassen (Denmark)

Targeting EGFR in non-small cell lung cancer - new insights

Speaker: A. Psyrri (Greece)

Targeting EGFR in colorectal cancer - new insights

Speaker: H. Van Krieken (Netherlands)

Targeting PI3K/AKT and EGFR in head and neck cancer - new insights

Speaker: T. Van Der Kwast (Canada)

Targeting the androgen receptor in prostate cancer - new insights

Speaker: R. Cathomas (Switzerland)

Discussion & Roundup

Scientific Symposium: New Insights in Lung Cancer - Collection of Rare Cancers

16:45 - 18:15

F. Santarelli (Italy)

Co-Chair: U. Keilholz (Germany)

Targets in squamous cell carcinoma

Speaker: B. Besse (France)

Targets in adenocarcinoma

Speaker: J. S. C. Santos (France)

Targets in SCLC

Speaker: M. T. Portanier (USA)

Upfront biomarker analysis to guide stage VI treatment: Practical use

Speaker: S. Peters (Switzerland)

Discussion & Roundup

Scientific Symposium: New Insights in Lung Cancer - Collection of Rare Cancers

16:45 - 18:15

M. C. M. Pietanza (USA)

Co-Chair: R. Cathomas (Switzerland)

Targets in SCLC

Speaker: A. Casale (Italy)

Targets in non small cell lung cancer

Speaker: U. Keilholz (Germany)

Detection of predictive biomarkers in non small cell lung cancer

Speaker: M. Scher (USA)

Detection of predictive biomarkers in metastatic breast cancer

Speaker: M. Scher (USA)

Detection of predictive biomarkers in lung cancer with novel molecular tools

Speaker: T. Van Der Kwast (Canada)

Detection of predictive biomarkers in prostate cancer with novel molecular tools

Speaker: T. Van Der Kwast (Canada)

Detection of predictive biomarkers in colorectal cancer with novel molecular tools

Speaker: M. Scher (USA)

Detection of predictive biomarkers in breast cancer with novel molecular tools

Speaker: M. Scher (USA)

Detection of predictive biomarkers in melanoma with novel molecular tools

Speaker: M. Scher (USA)

Detection of predictive biomarkers in head and neck cancer with novel molecular tools

Speaker: T. Van Der Kwast (Canada)

Detection of predictive biomarkers in gynaecological cancers with novel molecular tools

Speaker: M. Scher (USA)

Discussion & Roundup
**Sunday 27 September 2015**

**Multidisciplinary Tumour Board: Breast Cancer**
- 11:30 - 12:30
  - Chair: J. van de Kerkhof (Belgium)
  - Case presentation by young oncologist: Early disease
  - Speaker: F. Cellini (Italy)
  - Panel Discussion: Early disease
  - Case presentation by young oncologist: Locally advanced disease
  - Speaker: A. Legras (France)
  - Panel Discussion: Locally advanced disease
  - Case presentation by young oncologist: Advanced disease
  - Speaker: M. Eriksson (Sweden)
  - Panel Discussion: Advanced disease
  - Radiation Oncologist: T. van der Kwast (Canada)
  - Surgical Oncologist: J.S.A. Belderbos (Netherlands)
  - Pathologist: T. Van der Kwast (Canada)
  - Oncology Nurse: K. Cedermark (Sweden)
  - Special Session: Management of Sarcoma Patients in Reference Centres
    - 11:30 - 12:30
      - Chair: S. Bonvallet (France)
      - Scandinavian experience
        - Speaker: M. Eriksson (Sweden)
      - Treatment in reference centres: The turning point in UK
        - Speaker: J. Judson (United Kingdom)
      - Why is it difficult to implement? Next steps
        - Speaker: A. Haas (Netherlands)
      - Recent data: Are promises fulfilled?
        - Speaker: J. Ray-Coquard (France)
  - Discussion & Voting

**Colorectal Cancer**
- 11:30 - 12:30
  - Case presentation by young oncologist: Locally advanced disease
  - Speaker: E. Vicini (Italy)
  - Panel Discussion: Locally advanced disease
  - Case presentation by young oncologist: Advanced disease
  - Speaker: M. Campone (France)
  - Panel Discussion: Advanced disease
  - Radiation Oncologist: B. Tombal (Belgium)
  - Surgeon Oncologist: J.R. Van der Vorst (Netherlands)
  - Pathologist: J. Barentsz (Netherlands)
  - Oncology Nurse: V. Khoo (United Kingdom)
  - Discussion: This House Believes that Molecular Diagnosis of Sarcoma is a Luxury
    - 11:30 - 12:30
      - Chair: S. Bonvallet (France)
      - Scandinavian experience
        - Speaker: M. Eriksson (Sweden)
      - Treatment in reference centres: The turning point in UK
        - Speaker: J. Judson (United Kingdom)
      - Why is it difficult to implement? Next steps
        - Speaker: A. Haas (Netherlands)
      - Recent data: Are promises fulfilled?
        - Speaker: J. Ray-Coquard (France)
  - Discussion & Voting

**Scientific Symposium: Therapeutic Implication of Intra Tumour Heterogeneity in Breast Cancer**
- 12:30 - 13:30
  - Chair: A. Barron-Doyle (New Zealand)
  - Case presentation by young oncologist: Early disease
    - Speaker: E. De Vries (Netherlands)
  - Panel Discussion: Early disease
  - Case presentation by young oncologist: Locally advanced disease
    - Speaker: T. Lebret (France)
  - Panel Discussion: Locally advanced disease
  - Case presentation by young oncologist: Advanced disease
    - Speaker: M. V. Dieci (Italy)
  - Panel Discussion: Advanced disease
  - Urologist: E. Vicini (Italy)
  - Radiologist: J. Vansteenkiste (Belgium)
  - Pathologist: J. Barentsz (Netherlands)
  - Discussion & Roundup

**Scientific Symposium: Muscle Invasive Bladder Cancer**
- 12:30 - 13:30
  - Chair: T. de Roeye (Netherlands)
  - Co-Chair: C.N. Sternberg (Italy)
  - Case presentation by young oncologist: Early disease
    - Speaker: J.-R. Van der Vorst (Netherlands)
  - Panel Discussion: Early disease
  - Case Presentation by young oncologist: Locally advanced disease
    - Speaker: T. Lebret (France)
  - Panel Discussion: Locally advanced disease
  - Case presentation by young oncologist: Advanced disease
    - Speaker: M. V. Dieci (Italy)
  - Panel Discussion: Advanced disease
  - Radiation Oncologist: F. Cardoso (Portugal)
  - Medical Oncologist: J. Barentsz (Netherlands)
  - Urologist: J. Barentsz (Netherlands)
  - Discussion & Roundup

**Scientific Symposium: New Drugs on the Horizon II**
- 09:45 - 10:45
  - Chair: E. Raymond (Switzerland)
  - Co-Chair: M.E. Scheulen (Germany)
  - TNBC: Biomarkers and opportunities for individualised therapy
    - Speaker: F. Cardoso (Portugal)
  - Prostate cancer: From therapeutic nihilism to diversity in treatment options: what can be added?
    - Speaker: A. R. Vendel (Belgium)
  - Multiple myeloma: Of new drugs and new combinations
    - Speaker: F. Abraham (France)
  - Discussion & Roundup

**Scientific Symposium: Gastrointestinal Malignancies - Colorectal Cancer**
- 11:30 - 12:30
  - Chair: P. Moreau (France)
  - New combinations
    - Speaker: B. Tombal (Belgium)
  - Biomarkers in bladder cancer
    - Speaker: J. Barentsz (Netherlands)
  - Surgical treatments: What is new?
    - Speaker: T. Lebret (France)
  - Discussion & Roundup

**Special Session: The Molecular and Histological Classification of Gastro-Oesophageal Cancer: Implications for Treatment**
- 11:30 - 12:30
  - Chair: M. Pedalino (Spain)
  - Classification of OG Cancer through distinct molecular subgroups
    - Speaker: A. Bass (Italy)
  - Implications for therapeutic exploitation
    - Speaker: D. Cunningham (United Kingdom)
  - Tailored surgical approach
    - Speaker: F. Mollol (Italy)
  - Discussion

**Melanoma**
- 11:30 - 12:30
  - Chair: J. Futterer (Netherlands)
  - Immunotherapy: Is there any predictive biomarkers?
    - Speaker: L. Zaccaria (France)
  - The role circulating tumour cells in melanoma
    - Speaker: C. Druge (United Kingdom)
  - cfDNA
    - Speaker: A. Pivonka (France)
  - Discussion
Scientific Symposium: Personalised Medicine: Biomarkers, Surrogacy and Companion Diagnostics

17:00 - 18:30
Chair: S. Leduc (Belgium)
Co-Chair: L. Siu (Canada)

Pharmacologic biomarkers in the development of stratified cancer medicine
Speaker: M. Buyse (Belgium)

One size doesn’t fit all - current status of commonly used surrogate markers across tumours: Paradigms from colorectal, lung and breast cancer
Speaker: M. Reck (Germany)

Co-Chair: M. Reck (Germany)
Chair: L. Paz-Ares (Spain)

09:00 - 11:00
◼

Saturday 26 September 2015

PATIENT ADVOCACY

Patient Advocacy Session: Ensuring Quality of Treatment
10:45 - 11:45
Chair: P. Siu (Canada)

What are generics and biosimilars?
Speaker: R. Bergström (Belgium)

Counterfeits: Generics, substandard drugs, counterfeit medicines - what is the difference?
Speaker: J. Geissler (Germany)

Regulating medicines and medical devices
Speaker: To be announced

The European Atlas of Access to Myeloma Treatment
Speaker: E. Sauvage (Germany)

Discussion

Patient Advocacy Session: Rehabilitation
09:15 - 11:15
Chair: S. Sauvage (Germany)

Mentoring: Patients helping each other
Speaker: M. Wolf (Germany)

Create your future: Supporting survivors into the workforce
Speaker: S. Kaner (Australia)

Discussion

Adults
Chair: S. Sauvage (Germany)
Co-Chair: K. Oliver (United Kingdom)

Cancer in the workplace
Speaker: J. Banks (Belgium)

Your life: For patients who want to take action themselves
Speaker: S. Neumann (Denmark)

Rehabilitation: Summary and analysis of actions among European countries
Speaker: K. Oliver (United Kingdom)

Discussion

Patient Advocacy Session: Multidisciplinary Teams under the Microscope
15:15 - 16:15
Chair: P. Siu (Canada)

Pain, pride and prejudice
Speaker: K. Oliver (United Kingdom)

The patient and the pathologist
Speaker: K. Oliver (United Kingdom)

The bill of rights
Speaker: P. Siu (Canada)

Discussion

Patient Advocacy Session: Communication - Stop Press Session
17:00 - 19:00
Chair: J. Gietema (Netherlands)

Wrap-up discussion/recommendations from the patient advocacy track
Facilitators: J. Gietema (Netherlands)

Details to be announced in the online searchable programme and final programme as soon as possible

Monday 28 September 2015

Patient Advocacy Session: Clinical Trials - What Really Matters to Patients
09:15 - 10:45
Chair: M. Prat (Belgium)
Co-Chair: B. Raji (Switzerland)
Panel: A.M.M. Eggermont (France)
Panel: J. Bos (Netherlands)
Panel: L. Siu (Canada)
Panel: To be announced

Scientific Symposium: Making Survivor Care Evidence Based for the Growing Number of Survivors: Patients at the ForeFront of Their Own Survivorship Care

17:00 - 18:30
Chair: S. Dile (Turkey)
Co-Chair: M. Rock (Germany)

How late effects in testicular cancer guide follow-up
Speaker: P.S. Nuyens (Netherlands)

How to involve the primary care physician in survivor care for growing number of survivors
Speaker: E. Grunfeld (Canada)

Patients in control of navigating their own survivor care plan
Speaker: J. Gietema (Netherlands)

Discussion & Roundup

TUESDAY 29 SEPTEMBER 2015

Integrated Session: Immunotherapy in the Management of Metastatic Melanoma
11:35 - 12:35
Chair: P. Power (Netherlands)

Expanding the range of gene testing as next generation sequencing enters clinical practice
Speaker: F. Foschia (France)

Surgical strategies for gene carriers: Breast conservation versus unilateral or bilateral mastectomy
Speaker: O. Cerfontain (Italy)

Tailoring chemotherapy for hereditary breast cancer carriers
Speaker: T. Tass (United Kingdom)

Discussion

20:45 - 21:30
Chair: J. Dierks (Turkey)

What are generics and biosimilars?
Speaker: R. Bergström (Belgium)

Counterfeits: Generics, substandard drugs, counterfeit medicines - what is the difference?
Speaker: J. Geissler (Germany)

Regulating medicines and medical devices
Speaker: To be announced

The European Atlas of Access to Myeloma Treatment
Speaker: E. Sauvage (Germany)

Discussion

Patient Advocacy Session: Rehabilitation
09:15 - 11:15
Chair: S. Sauvage (Germany)

Mentoring: Patients helping each other
Speaker: M. Wolf (Germany)

Create your future: Supporting survivors into the workforce
Speaker: S. Kaner (Australia)

Discussion

Adults
Chair: S. Sauvage (Germany)
Co-Chair: K. Oliver (United Kingdom)

Cancer in the workplace
Speaker: J. Banks (Belgium)

Your life: For patients who want to take action themselves
Speaker: S. Neumann (Denmark)

Rehabilitation: Summary and analysis of actions among European countries
Speaker: K. Oliver (United Kingdom)

Discussion
**SARCOMA: SOFT TISSUE AND BONE**

**Saturday 26 September 2015**

**Teaching Lecture: Is There Any New Treatment in Metastatic STS?**
- 07:45 - 08:30
  - Chair: J. Judson (United Kingdom)
  - Speaker: Y. Ueki (France)

Special Session: Successes and Uncertainties for Targeted Therapies of Sarcomas
- 09:15 - 10:15
  - Chair: S. Bonvalot (France)
  - Speaker: P. Bhatia (United Kingdom)

**MDM2/CDK4: Good targets?**
- Speaker: M. D’Incalci (Italy)

**Trabectedine and M2 macrophages**
- 15:15 - 16:15
  - Chair: I. Judson (United Kingdom)

**Therapies of Sarcomas**
- Uncertainties for Targeted
- Special Session: Successes and Uncertainties for Targeted Therapies of Sarcomas
- 07:45 - 08:30
  - Chair: I. Judson (United Kingdom)

**Recent data: Are promises fulfilled?**
- 11:30 - 12:30
  - Chair: S. Bonvalot (France)
  - Speaker: R. Haas (Netherlands)

**Scientific Question**
- Treatment Is the Key Medical
- Supportive Care and Palliation
- Saturday 26 September 2015
- Scientific Symposium: ECCO/MASCC Joint Symposium
- 16:45 - 18:15
  - Details to be announced in the online searchable programme and final programme as soon as possible

**Surgical Oncology**
- Saturday 26 September 2015
- Scientific Symposium: How to Select the Best Palliative Treatments on the Basis of Survival and Treatment Outcome
- 10:00 - 10:30
  - Chair: Y. Van der Ven (Netherlands)
  - Speaker: P. Naredi (Sweden)

**Scientific Symposium: ECCO/MASCC Joint Symposium**
- **Discussion & Roundup**

**Sunday 27 September 2015**

**Teaching Lecture: Long Term Physical Outcomes of Bone Sarcoma Surgery in Children and Young Adults**
- 08:00 - 08:45
  - Chair: R. Ladenstein (Austria)
  - Speaker: R. Grimer (United Kingdom)

**Scientific Symposium: Local Treatment is the Key Medical Scientific Question**
- 09:45 - 10:45
  - Chair: S. Bonvalot (France)
  - Co-Chair: P. Bhatia (United Kingdom)

**Quality assurance in surgery**
- Speaker: A. Corner (Italy)

**Hallmarks of hyperthermia**
- Speaker: A. Gliozzi (Italy)

**Nanoparticle therapies**
- Speaker: S. Bonvalot (France)

**New questions for RT in randomised trials**
- Speaker: R. Haas (Netherlands)

**Discussion & Roundup**
- Special Session: Management of Sarcoma Patients in Reference Centres
  - **Debate: This House Believes that Molecular Diagnosis of Sarcoma is a Luxury**
    - 15:30 - 16:15
      - Moderator: E. de Alba (Spain)
      - Speaker in favour: J. Van der Ven (Netherlands)
      - Speaker against: Y. Van der ven (Netherlands)
      - Second in favour: W.T.A. van der Graaf (Netherlands)
      - Second in against: A. Le Cesne (France)

**Supportive Care and Palliation**
- **Debate: This House Believes that Molecular Diagnosis of Sarcoma is a Luxury**
  - 15:30 - 16:15
    - Moderator: E. de Alba (Spain)
    - Speaker in favour: J. Van der Ven (Netherlands)
    - Speaker against: Y. Van der ven (Netherlands)
    - Second in favour: W.T.A. van der Graaf (Netherlands)
    - Second in against: A. Le Cesne (France)

**Discussion & Voting**
- 15:15 - 16:15
  - Chair: M. D’Incalci (Italy)
  - Speaker: G. Zecevic (France)

**Scientific Symposium: Developing and Testing supportive Care Interventions**
- 08:00 - 08:45
  - Chair: A. Mergen (Switzerland)
  - Speaker: M. Eicher (Switzerland)

**Scientific Symposium: ECCO/MASCC Joint Symposium**
- 16:45 - 18:15
  - Details to be announced in the online searchable programme and final programme as soon as possible

**Monday 28 September 2015**

**Teaching Lecture: Developing and Testing Supportive Care Interventions**
- 08:00 - 08:45
  - Chair: A. Mergen (Switzerland)
  - Speaker: M. Eicher (Switzerland)

**Special Session: Management of Sarcoma Patients in Reference Centres**
- **11:30 - 12:30**
  - Chair: S. Bonvalot (France)
  - Special Session: The Challenge of Spiritual Caring in Supportive Care and Palliation
    - 13:30 - 15:15
      - Chair: A. Chahreboi (Cypus)
      - What does spiritual caring mean - from patient perspective
        - Speaker: C. Ruschak (USA)
      - Why is it difficult to care for the patient spiritually?
        - Speaker: O. Aleksichina (Malta)

**Thursday 24 September 2015**

**Teaching Lecture: Surgery in Synchronous Oligometastatic Disease**
- 07:45 - 08:30
  - Chair: C. Van der Ven (Netherlands)
  - Speaker: P. Naredi (Sweden)

**Society Session: European Society of Surgical Oncology (ESSO)**
- 10:30 - 12:30
  - Chair: R.A. Audisio (United Kingdom)
  - Speaker: S. Gonzalez-Moreno (Spain)
  - Presentation of the ESSO Award
    - Speaker: C. Wyld (United Kingdom)
  - UEMLS approved Surgical Curriculum
    - Speaker: C. Wyld (United Kingdom)
  - The training in surgical oncology across the EU
    - Speaker: J. Van der ven (Netherlands)
  - Travelling fellowship in surgical oncology across the Atlantic
    - Speaker: D. Perez (Germany)

**Friday 25 September 2015**

**Teaching Lecture: High-Grade Primary Soft Tissue and Bone Sarcomas**
- 09:00 - 10:00
  - Chair: J.F. Bosset (France)
  - Speaker: S. Gonzalez-Moreno (Spain)

**Scientific Symposium: How to Select the Best Palliative Treatments on the Basis of Survival and Treatment Outcome**
- 10:00 - 10:30
  - Chair: Y. Van der Ven (Netherlands)
  - Speaker: P. Naredi (Sweden)

**Discussion & Roundup**
- 15:15 - 16:15
  - Chair: S. Gonzalez-Moreno (Spain)

**Learning curve for complex cancer surgery**
- Speaker: P. Bhatia (United Kingdom)

**Locally advanced pelvic lesions**
- Surgical: L. Chieb (Italy)

**Robotic: Nurse’s role in high-tech surgical theatres**
- Speaker: M. Dana (Italy)

**Discussion**
- Educational Symposium: New Drugs for Symptom Management of Pain, Cancer Cachexia and Depression in Cancer Patients
  - 09:00 - 10:00
    - Chair: A. Cervantes (Spain)
    - Speaker: S. Gonzalez-Moreno (Spain)

**Sarcoma Surgery in Children and Physical Outcomes of Bone Sarcoma Surgery in Children and Young Adults**
- 08:00 - 08:45
  - Chair: S. Bonvalot (France)
  - Speaker: P. Bhatia (United Kingdom)
  - Nurses’ perspectives on supporting prognostic information in palliative care
    - Speaker: I. Folksorschield (United Kingdom)

**Discussion & Roundup**
- **Discussion & Roundup**
  - Speaker: M. Fallon (United Kingdom)
  - Cancer pain: New drugs and interventions
    - Speaker: S. Kaasa (Norway)

**Psychosocial support for dying children and their parents: The nursing role**
- Speaker: T. Tiso (Cyprus)

**SUPPORTIVE CARE**
- Saturday 26 September 2015
- **Teaching Lecture: Surgery in Synchronous Oligometastatic Disease**
  - 07:45 - 08:30
    - Chair: C. Van der Ven (Netherlands)
    - Speaker: P. Naredi (Sweden)

**Society Session: European Society of Surgical Oncology (ESSO)**
- 10:30 - 12:30
  - Chair: R.A. Audisio (United Kingdom)
  - Speaker: S. Gonzalez-Moreno (Spain)
  - Presentation of the ESSO Award
    - Speaker: C. Wyld (United Kingdom)
  - UEMLS approved Surgical Curriculum
    - Speaker: C. Wyld (United Kingdom)
  - The training in surgical oncology across the EU
    - Speaker: J. Van der ven (Netherlands)
  - Travelling fellowship in surgical oncology across the Atlantic
    - Speaker: D. Perez (Germany)

**The surgical lead of MDTs**
- Speaker: R. van der Voort (United Kingdom)

**Virtual reality, cadaver lab and tele-tutoring: Can new teaching paradigm decrease learning curves assuring surgical quality?**
- Speaker: G.Topics (Italy)

**Questions & Answers**
- **Special Session: Highly Skilled Surgery and Patients Outcomes**
  - 15:30 - 16:30
    - Chair: S. Gonzalez-Moreno (Spain)

**Learning curve for complex cancer surgery**
- Speaker: P. Bhatia (United Kingdom)

**Locally advanced pelvic lesions**
- Surgical: L. Chieb (Italy)

**Robotic: Nurse’s role in high-tech surgical theatres**
- Speaker: M. Dana (Italy)

**Discussion**
- Educational Symposium: New Drugs for Symptom Management of Pain, Cancer Cachexia and Depression in Cancer Patients
  - 09:00 - 10:00
    - Chair: A. Cervantes (Spain)
    - Speaker: S. Gonzalez-Moreno (Spain)

**Sarcoma Surgery in Children and Physical Outcomes of Bone Sarcoma Surgery in Children and Young Adults**
- 08:00 - 08:45
  - Chair: S. Bonvalot (France)
  - Speaker: P. Bhatia (United Kingdom)
  - Nurses’ perspectives on supporting prognostic information in palliative care
    - Speaker: I. Folksorschield (United Kingdom)

**Discussion & Roundup**
- **Discussion & Roundup**
  - Speaker: M. Fallon (United Kingdom)
  - Cancer pain: New drugs and interventions
    - Speaker: S. Kaasa (Norway)

**Psychosocial support for dying children and their parents: The nursing role**
- Speaker: T. Tiso (Cyprus)
## Sunday 27 September 2015

### Special Session: Excisional Margins in 2015
- **15:15 - 16:15**
  - Chair: J.R. Van der Vorst (Netherlands)
  - Is the excisional margin important in breast cancer treatment?
    - Speaker: T. Rejniak (France)
  - What minimal excisional margin in liver surgery can be accepted?
    - Speaker: C. Potsin (United Kingdom)
  - Local recurrence after radically resected pancreatic cancer - what have we missed?
    - Speaker: C. Verheul (Sweden)
  - Discussion

### Monday 28 September 2015

#### Teaching Lecture: Radical Approach to Peritoneal Surface Malignancies using Cytoreductive Surgery
- **08:00 - 08:45**
  - Chair: S. Gonzalez-Moreno (Spain)
  - Specialist treatment for elderly cancer patients
    - Speaker: T. Czernobilsky (Austria)
  - Selection for risk reduction surgery in hereditary syndromes
    - Speaker: T. Czernobilsky (Austria)
  - Individualized treatment for elderly cancer patients
    - Speaker: R.A. Auvinen (United Kingdom)
  - Have guidelines improved outcomes or not?
    - Speaker: S. Sanduzzi (Italy)
  - Discussion

### Young Oncologists

#### Saturday 26 September 2015

**Young Oncologists Mentorship Session 1**
- **16:45 - 18:15**
  - Chair: S. Pastel-King (France)
  - Germ line genetic testing for cancer patients
    - Speaker: T. Reijnsveld (Netherlands)
  - Implementation of widespread BRCA testing - the genetologist’s perspective
    - Speaker: S. Vanasse (United Kingdom)
  - Molecular profiling of cancers - clinical utility and limitations
    - Speaker: S. Varamis (Italy)
  - What do cancer patients understand about genetic testing?
    - Speaker: J. Cottet (Germany)
  - Discussion

#### Sunday 27 September 2015

**Special Session: How to Improve Cancer Training and Career Planning?**
- **19:30 - 21:00**
  - Chair: S. Banerjee (United Kingdom)
  - Oncological surgical training and career plans
    - Speaker: S. Banerjee (United Kingdom)
  - Medical oncology training and career plans
    - Speaker: R. Popescu (Switzerland)
  - Oncological surgical training and career plans
    - Speaker: R. Popescu (Switzerland)
  - Discussion

### Oncology Career Choices for You

- **13:00 - 14:30**
  - Chair: S. Gonzalez-Moreno (Spain)
  - Radiation Oncology
    - Mentor: A. Cervantes (Spain)
  - Medical Oncology
    - Mentor: T. Helleday (Sweden)
  - Basic/Translational Research
    - Mentor: A. Margulies (Switzerland)
  - Discussion

### Young Oncologists Mentorship Session 2
- **19:30 - 21:00**
  - Chair: S. Banerjee (United Kingdom)
  - Radiation Oncology
    - Mentor: J. van der Vorst (Netherlands)
  - Medical Oncology
    - Mentor: J. van der Vorst (Netherlands)
  - Basic/Translational Research
    - Mentor: R. Marais (United Kingdom)
  - Discussion

### Young Oncologists Mentorship Session 3
- **13:00 - 14:30**
  - Chair: S. Banerjee (United Kingdom)
  - Radiation Oncology
    - Mentor: A. Baildam (United Kingdom)
  - Medical Oncology
    - Mentor: A. Mucici (Italy)
  - Basic/Translational Research
    - Mentor: R. Marais (United Kingdom)
  - Discussion
Young Oncologists @ ECC2015

Undoubtedly, the European Cancer Congress is the must-attend event for all young oncologists in Europe in 2015.

The Congress is the leading European platform for presenting practice-changing scientific data and a unique multidisciplinary context where different areas of oncology converge to explore innovative solutions to help cancer patients. These factors combine to create the best environment to foster the professional growth of a young oncologist.

However, the European Cancer Congress traditionally does much more than that for our promising young oncologists and ECC2015 takes this tradition even further.

The programme includes a special track dedicated to young professionals in the field of oncology. This track is designed to provide advanced knowledge building a bridge between scientific progress and the clinical setting (“Cancer Genetics for Oncologists – Issues in Clinical Practice”) as well as provide deeper understanding of broader aspects of cancer care (“How to Break Significant News”).

At the same time, the Congress programme makes a point of providing invaluable mentorship opportunities for young oncology professionals. The Congress gathers in one place the most brilliant scientists and practitioners who have a strong commitment to the sharing of their experience and wisdom with the new generation of specialists. At ECC2015, young oncologists will be able to participate in special mentorship sessions designed to ensure this handover of learning acquired through a wealth of experience at the highest level of oncology practice.

Learning won't stop there – the programme will offer sessions focused on key topics that affect every young oncologist in Europe. Experts will offer guidance on issues such as career opportunities in Europe and making the right choices among them, improving cancer training and avoiding burnout by ensuring a good work/life balance.

The Congress offers numerous networking opportunities which will help young specialists build invaluable and enduring working relationships to support their professional future.

We encourage young oncologists to register early for ECC2015 and make the most of this extraordinary career-making event!
Patient Advocacy @ ECC2015

Developments and innovations in oncology that will lead to better outcomes can only happen by listening to patients. Without actively listening to the needs and wishes of patients, it will be impossible to fully understand and assess whether treatments are effective and this will be particularly important with the growth of personalised medicine. This is why the ECC Patient Advocacy Track Chair and experts have worked together with ECC2015 scientific track chairs to enrich the scientific programme with the patient perspective.

Patient advocates will participate in a roundtable discussion on oncology drug development in the era of genomic sequencing and will contribute their views on the evaluation of the clinical benefit of cancer drugs as well as what matters to patients in clinical trials.

The perspective of patients on survivor care will be provided in a scientific symposium looking for ways to make survivor care evidence-based for the growing number of survivors. Empowering each survivor to play a leading role in his/her own care will be a recurring theme at ECC2015. The European Cancer Congress will re-examine and shed new light on key topics for patients and survivors so that stakeholders can explore areas of collaboration particularly aimed at tackling inequalities in cancer care. A full session will look at the flow of information between healthcare professionals and patients and address topics like communication skills that facilitate shared decision making, dealing with fear both from a patient and from a healthcare professional perspective, communication on issues of sexuality and all other quality of life angles.

ECC2015 will provide educational opportunities for patient advocates so they can deepen their understanding of topics such as genetic and biomolecular testing, generics and sub-standard drugs.

Attendance scholarships covering travel and registration costs will be available to patient advocates to facilitate their participation at the European Cancer Congress.

Details will be published on www.europeancancercongress.org

Oncopolicy Forum

Unique to the European Cancer Congress is the inclusion of a track dedicated to public policy in cancer control, featuring the most pertinent issues faced by practitioners and other actors across the cancer continuum. The Oncopolicy Forum (OPF) harnesses the expertise and experience of the entire oncology community to bridge the gap between science and policy, and maximise the potential for achieving positive policy development with patient interests at the core.

The OPF has repeatedly re-affirmed itself as a unique platform for fruitful exchange between experts across the cancer continuum and decision-makers, leading to increased understanding of mutual needs and priorities towards informed policy making and tangible change.

The previous edition of the Oncopolicy Forum dealt with issues such as innovative approaches to the organisation of personalised cancer care across Europe, facilitating personalised care for rare cancer patients through European Reference Networks, and aligning evidence and policy for the optimal prioritisation of scarce resources in oncology. High level participants included the Commissioner for Health Tonio Borg and Member of the European Parliament Teresa Riera Madurell, Rapporteur on the Horizon 2020 Programme for Research and Innovation.

This year’s OPF will once more look at the most pressing issues in oncology and how public policy can play an important role in providing cancer care professionals, researchers and patients with the political and regulatory frameworks necessary to advance patient outcomes.

On Saturday 26 September, the OPF2015 will kick-off with the first in a series of ‘Timebombs in oncology’, starting with cancer survivorship. This timebomb poses many policy challenges including how to implement effective ‘back to work’ schemes for those willing and able to return to the workplace. Cancer in the elderly will be in focus on Sunday 27 September. With the retirement age increasing in many countries, the number of people working with long-term medical conditions including certain cancers will also increase. Some employers have recognised this and are implementing workplace initiatives to address the problem. Finally, the oncology workforce will be put under the microscope on Monday 28 September and discussion with the audience will seek to solicit possible policy solutions in anticipation of workforce shortages in essential disciplines.

Inequalities in treatment outcomes - both between and within European countries - are among the other topical issues at the OPF2015. Thus, on Sunday 27 September, we will look at the current state of affairs and evaluate the multi-stakeholder effort required to ensure effective equality of access to treatment and medicines.

Another important session on Monday 28 September will unlock the possibilities for cancer research funding under the EU budget 2014 – 2020. It will enable participants to understand the sometimes complex landscape and identify the most relevant opportunities to benefit from available programmes, such as Horizon 2020. On the same day, the OPF2015 will address the critical developments on cross-border movement of cancer patients and the setting up of brand-new European Reference Networks in rare cancers.

OPF participants will have the opportunity to engage as part of an exceptional pool of multi-disciplinary cancer stakeholders – patients and professionals, to raise awareness on the issues in day-to-day oncology care, and ultimately contribute to influencing policy making in Europe.
Call for Abstracts

When to Submit

Abstract submission open: 26 January 2015
Abstract submission deadline: 28 April 2015, 21:00 Central European Time

Abstracts submitted after the stipulated deadline will not be considered. Authors are strongly advised to submit prior to the deadline and avoid unnecessary delays which may affect the standing of their abstract.

Abstract Policy and Regulations

Abstracts on case studies will be rejected.

With the submission of an abstract to European Cancer Congress 2015, the presenting author:

- Certifies to be an investigator with substantial involvement in the clinical study presented in the abstract.
- Accepts responsibility for the accuracy of the submitted abstract.
- Accepts to be the contact person for all correspondence regarding the abstract and informs co-authors of its status.
- Confirms that all co-authors are aware of and agree to the content of the abstract and support the data presented.
- Warrants that the data and conclusions presented in the abstract have not been presented or published at any meeting of 500 delegates or more prior to the European Cancer Congress 2015.
- Agrees to submit updated data for important large studies presented in part at previous meetings. Violation of this policy may result in rejection of the submitted abstract.

- Certifies that the information in the abstract is for exclusive presentation in the European Cancer Congress 2015 Scientific Programme and will not be presented during the ECC2015 at any Satellite Symposium.
- States that for all studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and informed consent given where appropriate.
- For abstracts containing clinical trial data include: Trial abbreviation, Trial Registry Number or ID background; Objective, Design, Population studied (including sample size), Intervention, Outcome measure(s), Analysis, Trial status, Trial sponsor(s)
- Identifies, obtains and discloses any financial interest in products or processes described in the abstract for all abstract authors. This includes stock ownership, membership on an advisory board or board of directors, corporate-sponsored research and other substantive relationships.
- Releases the copyright on behalf of all authors, to ECCO and gives permission for the abstract, when selected for presentation, to be published in the European Cancer Congress 2015 Abstract book - a European Journal of Cancer Supplement (in electronic format), as well as on the ECC2015 website.
- Identifies, obtains and discloses any financial interest in products or processes described in the abstract for all abstract authors. This includes stock ownership, membership on an advisory board or board of directors, corporate-sponsored research and other substantive relationships.
- Releases the copyright on behalf of all authors, to ECCO and gives permission for the abstract, when selected for presentation, to be published in the European Cancer Congress 2015 Abstract book - a European Journal of Cancer Supplement (in electronic format), as well as on the ECC2015 website.

- Trials in Progress abstracts and encore presentations will not be accepted.

Abstract Selection Process

Abstracts submitted for presentation in the European Cancer Congress 2015 will be reviewed by an international panel of experts in the field of the subject and will be judged solely on the data submitted. The final decision on the presentation format of all selected abstracts lies at the sole discretion of the Scientific Committee.

The following presentation formats are applicable at the European Cancer Congress 2015:

- Oral presentation
  The abstract is selected for oral presentation in one of the proffered papers sessions. Abstracts of superior quality can be selected for presentation in a session where discussants will place the research findings into perspective.

- Poster Presentation
  Abstracts that have been selected for poster presentation will be displayed on poster boards in a prominent poster viewing area next to the exhibition. The posters will be grouped by topic and displayed for four hours each. A specific time will be devoted to poster viewing to ensure delegates have sufficient opportunity to acquaint themselves with the presented data.

- Poster Discussion
  Prominent experts will provide a thematic overview and discuss the findings from selected abstracts chosen for poster presentation. Delegates will be offered an expert review-at-a-glance of the presented findings and will be able to further refine their interest in specific abstracts.

- Poster Spotlight Sessions
  The Scientific Committee will make a special selection of posters which will be highlighted through short oral presentations followed by moderated discussion. These sessions will facilitate dynamic exchange on selected findings of broad interest.

Abstract Withdrawal

ECCO cannot guarantee any request for withdrawal of an abstract that in any way delays the ECC2015 publications. Requests to withdraw abstracts will be accepted until 10 July 2015. After this date, abstracts selected for presentation must be presented. If the presenting author of a selected abstract cannot attend, they should assign a replacement and inform ECCO of the replacement as soon as possible.

The presenting author will receive a letter with the result of the review and the Scientific Committee’s decision on the abstract by early July.

Abstract Submission Fee

Each submitted abstract must be accompanied by a 35 EUR abstract submission fee. The submission fee can only be paid by credit card. This fee is non-refundable regardless of the final status of the abstract.

Note: Submitting an abstract for presentation in the European Cancer Congress 2015 does not constitute registration for the Congress. Abstract presenters must register to attend the European Cancer Congress 2015.

Late-Breaking Abstracts

Abstract submission open: 22 July 2015
Abstract submission deadline: 5 August 2015, 21:00 Central European time

Late-breaking abstracts describe the latest advances that will change our daily clinical practice. They should highlight novel and practice-changing studies. Focus is placed on capturing abstracts with ground-breaking and unique data that would not otherwise have been presented at the Congress.

Examples of suitable late-breaking abstracts might include the results of a practice-changing prospective Phase III clinical trial; a Phase II study showing anti-tumour activity in a novel context; an early clinical trial with novel proof-of-principle data, or the demonstration of novel
cancer biology with therapeutic implications – in each case the results should not have been fully available by the regular abstract submission deadline.

Note: The late-breaking abstract deadline is not an extension of regular abstract submission deadline.

Policy & Regulation
Abstracts from translational, Phase I, Phase II or Phase III studies for which preliminary data were not available at the time of the regular abstract submission deadline will be considered.

Data from the long-term follow-up of previously presented clinical trials may be submitted only if significant new information can be shown.

Interim analysis of a prospective randomised clinical trial will be considered only if it is performed as planned in the original protocol and is statistically valid. If your abstract involves interim analysis, explain the details of your study in the body of the abstract.

The data in the abstract cannot be published (manuscript or abstract) prior to the Congress.

With the submission of a late-breaking abstract to European Cancer Congress 2015, the presenting author must:

Submit by the deadline of 5 August 2015.

Provide rationale on why the abstract should be considered as late-breaking (complete this section in the submission system).

Ensure submission of the abstract adheres to the regular abstract submission policy and regulations in addition to the specific guidelines listed above.

Ensure that abstracts contain final results and incorporate statistical analysis. Abstracts submitted stating “results to follow” or similar deferment will not be considered.

Submission
Late-breaking abstracts can only be submitted online through the submission system which will be available on the Congress website from 22 July 2015 until 5 August 2015.

Please refer to the Abstract Submission Fee section in the Call for Abstracts.

Selection
All late-breaking abstracts will undergo a formal peer-review evaluation by the Executive Scientific Committee and will be judged solely on the data submitted. The final decision on the status of the abstract lies with the Scientific Committee.

Late-breaking abstracts will only be considered for oral presentation in Proffered Paper sessions or the Presidential sessions. If a late-breaking abstract does not meet the criteria for oral presentation, the abstract will be rejected.

The presenting author will receive confirmation of acceptance or rejection by 20 August 2015. For questions regarding the submission process, e-mail abstracts@ecco-org.eu

Embargo Policy
Late-breaking abstracts and abstracts selected for media for the European Cancer Congress 2015 are embargoed until the first day of presentation. Information contained in the abstract as well as additional data and information to be presented must not be made public before the abstract has been presented at the ECCO2015. The first author and co-authors must not release the research/study to news media. If the policy is violated, the abstract will be automatically withdrawn from presentation and from publication online.

In case of any abstract related queries please contact: abstracts@ecco-org.eu

Abstract Topic Categories

<table>
<thead>
<tr>
<th>Topic Sub-Topic</th>
<th>Topic Sub-Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic Science</td>
<td>Cancer Screening and Prevention</td>
</tr>
<tr>
<td>Aging and Cancer, Telomerase</td>
<td>Primary Prevention</td>
</tr>
<tr>
<td>Animal Models of Cancer</td>
<td>Secondary Prevention</td>
</tr>
<tr>
<td>Ryrzand and Abscopal Effects</td>
<td>Tertiary Prevention</td>
</tr>
<tr>
<td>Cancer Cell Metabolism</td>
<td></td>
</tr>
<tr>
<td>Cancer Initiating Cells/Cancer Stem Cells</td>
<td></td>
</tr>
<tr>
<td>Cell Cycle, Cell Death, Senescence, Cell Proliferation</td>
<td></td>
</tr>
<tr>
<td>DNA Damage and Repair</td>
<td></td>
</tr>
<tr>
<td>Endpoints</td>
<td></td>
</tr>
<tr>
<td>Functional Genomics</td>
<td></td>
</tr>
<tr>
<td>Gene Expression, Transcriptional/Regulation</td>
<td></td>
</tr>
<tr>
<td>Genomic Alterations in Cancer</td>
<td></td>
</tr>
<tr>
<td>mRNA</td>
<td></td>
</tr>
<tr>
<td>Oncogenes</td>
<td></td>
</tr>
<tr>
<td>Receptor and Signal Transduction</td>
<td></td>
</tr>
<tr>
<td>Tumour Angiogenesis</td>
<td></td>
</tr>
<tr>
<td>Tumour Immunology</td>
<td></td>
</tr>
<tr>
<td>Tumour Microenvironment</td>
<td></td>
</tr>
<tr>
<td>Tumour Progression: Invasion and Metastasis</td>
<td></td>
</tr>
<tr>
<td>Tumour Suppressor Genes</td>
<td></td>
</tr>
<tr>
<td>Viral Oncogenesis</td>
<td></td>
</tr>
<tr>
<td>Early Drug Development</td>
<td></td>
</tr>
<tr>
<td>Angiogenesis Inhibitors</td>
<td></td>
</tr>
<tr>
<td>Apoptosis Inducers</td>
<td></td>
</tr>
<tr>
<td>Cyclins and CDKs</td>
<td></td>
</tr>
<tr>
<td>DNA Repair Mechanisms</td>
<td></td>
</tr>
<tr>
<td>Drug Design</td>
<td></td>
</tr>
<tr>
<td>Drug Resistance and Modifiers</td>
<td></td>
</tr>
<tr>
<td>Drug Screening</td>
<td></td>
</tr>
<tr>
<td>Drug Synthesis</td>
<td></td>
</tr>
<tr>
<td>Formulation Research</td>
<td></td>
</tr>
<tr>
<td>Monoclonal Antibodies and Targeted Therapeutics</td>
<td></td>
</tr>
<tr>
<td>Natural Products and Marine Compounds</td>
<td></td>
</tr>
<tr>
<td>New Molecular Targets</td>
<td></td>
</tr>
<tr>
<td>Radiation Interactive Agents</td>
<td></td>
</tr>
<tr>
<td>Signal Transmission Modulators</td>
<td></td>
</tr>
<tr>
<td>Telomerase Targeting Agents</td>
<td></td>
</tr>
<tr>
<td>Topoisomerase Inhibitors</td>
<td></td>
</tr>
<tr>
<td>Toxicology</td>
<td></td>
</tr>
<tr>
<td>Tubulin Interacting Agents</td>
<td></td>
</tr>
<tr>
<td>Tyrosine Kinase Inhibitors</td>
<td></td>
</tr>
<tr>
<td>Breast Cancer - Advanced Disease</td>
<td></td>
</tr>
<tr>
<td>Basic Science</td>
<td></td>
</tr>
<tr>
<td>Multi-Modality</td>
<td></td>
</tr>
<tr>
<td>Radiation Therapy</td>
<td></td>
</tr>
<tr>
<td>Surgery</td>
<td></td>
</tr>
<tr>
<td>Systems Therapy</td>
<td></td>
</tr>
<tr>
<td>Translational Research</td>
<td></td>
</tr>
<tr>
<td>Breast Cancer - Early Disease</td>
<td></td>
</tr>
<tr>
<td>Basic Science</td>
<td></td>
</tr>
<tr>
<td>Multi-Modality</td>
<td></td>
</tr>
<tr>
<td>Radiation Therapy</td>
<td></td>
</tr>
<tr>
<td>Surgery</td>
<td></td>
</tr>
<tr>
<td>Systems Therapy</td>
<td></td>
</tr>
<tr>
<td>Translational Research</td>
<td></td>
</tr>
<tr>
<td>Cancer in the Elderly</td>
<td></td>
</tr>
<tr>
<td>Epidemiology</td>
<td></td>
</tr>
<tr>
<td>Multi-Modality</td>
<td></td>
</tr>
<tr>
<td>Radiation Therapy</td>
<td></td>
</tr>
<tr>
<td>Surgery</td>
<td></td>
</tr>
<tr>
<td>Systems Science</td>
<td></td>
</tr>
<tr>
<td>Systems Therapy</td>
<td></td>
</tr>
<tr>
<td>Central Nervous System</td>
<td></td>
</tr>
<tr>
<td>Basic Science</td>
<td></td>
</tr>
<tr>
<td>Multi-Modality</td>
<td></td>
</tr>
<tr>
<td>Radiation Therapy</td>
<td></td>
</tr>
<tr>
<td>Surgery</td>
<td></td>
</tr>
<tr>
<td>Systems Therapy</td>
<td></td>
</tr>
<tr>
<td>Translational Research</td>
<td></td>
</tr>
<tr>
<td>Diagnostic Biomarkers</td>
<td></td>
</tr>
<tr>
<td>Biomarkers</td>
<td></td>
</tr>
<tr>
<td>Expression Profiling</td>
<td></td>
</tr>
<tr>
<td>Genetic Alteration</td>
<td></td>
</tr>
<tr>
<td>Early Drug Development</td>
<td></td>
</tr>
<tr>
<td>Angiogenesis Inhibitors</td>
<td></td>
</tr>
<tr>
<td>Apoptosis Inducers</td>
<td></td>
</tr>
<tr>
<td>Cyclins and CDKs</td>
<td></td>
</tr>
<tr>
<td>DNA Repair Mechanisms</td>
<td></td>
</tr>
<tr>
<td>Drug Design</td>
<td></td>
</tr>
<tr>
<td>Drug Resistance and Modifiers</td>
<td></td>
</tr>
<tr>
<td>Drug Screening</td>
<td></td>
</tr>
<tr>
<td>Drug Synthesis</td>
<td></td>
</tr>
<tr>
<td>Formulation Research</td>
<td></td>
</tr>
<tr>
<td>Monoclonal Antibodies and Targeted Therapeutics</td>
<td></td>
</tr>
<tr>
<td>Natural Products and Marine Compounds</td>
<td></td>
</tr>
<tr>
<td>New Molecular Targets</td>
<td></td>
</tr>
<tr>
<td>Radiation Interactive Agents</td>
<td></td>
</tr>
<tr>
<td>Signal Transmission Modulators</td>
<td></td>
</tr>
<tr>
<td>Telomerase Targeting Agents</td>
<td></td>
</tr>
<tr>
<td>Topoisomerase Inhibitors</td>
<td></td>
</tr>
<tr>
<td>Toxicology</td>
<td></td>
</tr>
<tr>
<td>Tubulin Interacting Agents</td>
<td></td>
</tr>
<tr>
<td>Tyrosine Kinase Inhibitors</td>
<td></td>
</tr>
<tr>
<td>Epidemiology</td>
<td></td>
</tr>
<tr>
<td>General Epidemiology</td>
<td></td>
</tr>
<tr>
<td>Genetic Epidemiology</td>
<td></td>
</tr>
<tr>
<td>Topic Sub-Topic</td>
<td>Topic Sub-Topic</td>
</tr>
<tr>
<td>----------------</td>
<td>----------------</td>
</tr>
<tr>
<td><strong>Gastrointestinal Malignancies - Colorectal Cancer</strong></td>
<td><strong>Head and Neck Cancer</strong></td>
</tr>
<tr>
<td>Basic Science</td>
<td>Basic Science</td>
</tr>
<tr>
<td>Multi-Modality</td>
<td>Multi-Modality</td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>Radiotherapy</td>
</tr>
<tr>
<td>Surgery</td>
<td>Surgery</td>
</tr>
<tr>
<td>Systemic Therapy</td>
<td>Systemic Therapy</td>
</tr>
<tr>
<td>Translational Research</td>
<td>Translational Research</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Fellowship Grants - Application

Fellowship grants will be made available to young oncology professionals (doctors, basic scientists, oncology nurses and radiotherapy technicians) to attend the 18th ECCO - 40th ESMO - European Cancer Congress.

ECCO member societies strongly believe in the importance of facilitating access to the Congress for young oncologists as a way to help them take their next steps towards professional excellence and best practice.

- 15 Fellowship grants are offered to young oncology professionals from countries with lower-middle income economies as per World Bank classification.
- 10 Fellowship grants are offered to young oncology professionals from Eastern European countries.

The following Member Societies will provide additional fellowship grants:

- EACR – 3 Fellowships (applicable to EACR members only)
- EONS – 5 Fellowships (applicable to EONS members only)
- ESMO – 3 Fellowships (applicable to ESMO members only)
- ESSO – 3 Fellowships (applicable to ESSO members only)
- SIOPE – 5 Fellowships (applicable to SIOPE members only)

Find out all you need to know on the requirements and the application process and deadlines at www.europeancancercongress.org

Novice Research Dissemination Award for Oncology Nurses

If this is the first time you have submitted an abstract for an international congress and you have less than five years’ experience doing research, your abstract may be considered for presentation in the ‘New Oncology Nursing Research’ session.

To be considered, you must tick the box entitled ‘Novice Research Dissemination Award’ during abstract submission. New oncology nursing researchers who tick this box and have their abstract accepted will be eligible for this new award.

All abstracts in this category will be judged by a panel, who will select 2 winners. Each award winner will receive free registration for ECC2015, and a contribution up to 1500 EUR will be reimbursed after the Congress to cover travel and accommodation.

ECCO/EJC Young Investigator’s Award

ECCO - the European Cancer Organisation and EJC - European Journal of Cancer are pleased to announce the ECCO/EJC Young Investigator’s Award, to be presented at 18th ECCO - 40th ESMO European Cancer Congress.

The ECCO/EJC Young Investigator’s Award is open to young basic scientists and clinical oncologists of all disciplines relevant to cancer research. The Award will be given to a young scientist or doctor in the field of basic, translational or clinical oncology research for recent original work in cancer research, treatment or care.

For details on the application criteria and process, visit www.europeancancercongress.org/EJC

Deadline for applications: 5 May 2015

Applications should be sent to Anne Blondeel, Congress Programme Coordinator via Email: anne.blondeel@ecco-org.eu
ESTRO AWARDS

ESTRO - VARIAN AWARD

A prize of 2,500 euros will be given to a radiation oncology professional for research in the field of radiobiology, radiation physics, clinical radiotherapy or radiation technology.

CRITERIA FOR ELIGIBILITY

1. Candidates should be ESTRO members, having completed the submitted work in the previous year.

2. Submissions should be brought forward by the candidates or their department heads and may be work done as an individual piece of research or as a thesis complete in the field of biological, physical and clinical research.

3. Candidates should be younger than 36. Exceptions will be made for female applicants who had to interrupt their research for pregnancy/maternity reasons; for them the maximum age is fixed at 40.

4. Candidates should submit:
   • A curriculum vitae and a list of publications
   • A copy of the abstract on the project which should have been submitted for the European Cancer Congress (indicate abstract title and submitting author with your application)
   • An English summary of their work (max 2 pages).

ESTRO - ACCURAY AWARD

A prize of 2,500 euros will be given to a radiation oncology professional for research in the field of “High Precision Radiotherapy”. Awardees may be qualified in the field of clinical radiotherapy, radiation physics, radiation technology or radiobiology.

CRITERIA FOR ELIGIBILITY

1. Candidates should be ESTRO Members, having completed the submitted work in the previous or current year.

2. Submissions should be brought forward by the candidates and may be work done as an individual piece of research or as a thesis completed in the field of biological, physical or clinical research.

3. Candidates should be younger than 36. Exceptions will be made for female applicants who had to interrupt their research for pregnancy/maternity reasons; for them the maximum age is fixed at 40.

4. Candidates should submit:
   • A curriculum vitae and a list of publications
   • A copy of the abstract on the project which should have been submitted for the European Cancer Congress (indicate abstract title and submitting author with your application)
   • An English summary of their work (max 2 pages).

APPLICATIONS FOR THE ABOVE LISTED AWARDS ARE TO BE ADDRESSED TO:

Eralda Azizaj
ESTRO Programme Manager
Rue Martin V 40, 1200 Brussels, Belgium
Tel. +32 2 775 93 40
E-mail: eralda.azizaj@estro.org
Deadline for submission: 1 April 2015
Global readership with an immediate and far-reaching impact

Publish with The Lancet Oncology, the global leader in clinical oncology, and open your research to the eyes and minds of oncologists around the world.

The Lancet Oncology has a global online audience of 16 million researchers, clinicians, and academics across 170 countries, who this year alone accessed more than 1 million articles from our online platforms; the journal is also free online to all low-to-middle income HINARI countries.

In fact, more than 11 000 oncologists in North America and over 5000 in Europe and Asia receive the full print journal. Key articles are featured in more than 3000 news stories annually and nearly 50 000 oncologists receive our e-alert announcements.

Ensure your research has an immediate and far-reaching impact. Publish with us and make a difference in the world of clinical oncology.

The European Cancer Congress 2015

GROUND-BREAKING RESEARCH TRANSFORMING MODERN ONCOLOGY

- Showcase your work at this unique multidisciplinary oncology platform
- Gain cutting-edge knowledge from a wealth of sessions tailored to your research interests:
  - A dedicated EACR society session
  - A Scientific Symposium on the Therapeutic Implication of Intra Tumour Heterogeneity in Breast Cancer, chaired by A. Børresen-Dale
  - A Scientific Symposium on the Mechanisms of Resistance to Targeted Therapies, chaired by R. Marais
  - An Integrated Session on Immunotherapy in the Management of Metastatic Melanoma, chaired by A. M. M. Eggermont

Full details on: www.europeancancercongress.org

Special rates for EACR members

Abstract submission deadline: 28 April 2015
Why You Should Participate at ECC2015

◼ Largest European Cancer Platform:
In 2015, the 18th ECCO – 40th ESMO European Cancer Congress (ECC2015) is the largest European multidisciplinary oncology platform for all oncology stakeholders to meet, learn and discuss new ground breaking data and share best practice to provide each cancer patient with optimal treatment and care.

◼ Impressive number of late-breaking abstracts presentations:
The European Cancer Congress is renowned for attracting and presenting a remarkable number of practice changing abstracts.

◼ Global Impact:
The abundance of practice-changing data presented at the European Cancer Congress is widely disseminated to a global readership thanks to our worldwide media coverage generated by the hundreds of journalists attending or reporting on the Congress.

◼ Unique Multidisciplinary Approach:
We have designed more integrated sessions bringing about dialogue and debate in overlapping areas of scientific research. The programme is therefore more streamlined, with fewer tracks, facilitating an even more productive experience for delegates.

◼ Oncopolicy:
The European Cancer Congress remains the only European cancer meeting with a dedicated Oncopolicy forum. The Oncopolicy Forum in Amsterdam tackled topics including research, personalised medicine and care, organisation of specialised care, and translation of evidence into policy. The recommendations derived from these discussions will be revisited at the Oncopolicy Forum in Vienna in 2015.

◼ Vienna, Trailblazer in Medicine – Host City:
Vienna is a natural host of ECC2015. Its track record as a leader in medical thought and practice speaks for itself – it has made its mark in key areas like radiotherapy, clinical diagnosis and public health to name a few.

Once again, ESSO has joined forces with the other founding members of ECCO-the European Cancer Organisation to offer an exciting scientific programme promoting multidisciplinarity.

The ECC2015 scientific programme will also feature a strong surgical oncology track throughout the meeting covering all aspects of the investigation and treatment of the common solid cancers that form the workload of cancer surgeons.

Don’t miss the opportunity to take part in the largest oncology congress in Europe!

• Submit an abstract and deliver your surgical messages to the largest multidisciplinary audience in Europe.
• Learn from leaders in the field of oncology and widen your network of peers.
• Take advantage of the significant discounted rates for ESSO members!

Highlights of the surgical track include:
• Special Session on Excisional Margins in 2015
• Special Session on The Right Surgery for the Right Patient: Predictions & Outcomes
• Special Session on Highly Skilled Surgery and Patients Outcomes
• Teaching Lecture on Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
• Teaching Lecture on Surgery in Synchronous Oligometastatic Disease
• Scientific Symposium on Neoadjuvant Treatment - When Is It of Benefit for the Patient and Doctor
• Society Award Session on Education in Cancer Surgery

More information on www.essoweb.org/events\ESSO35
Where cancer researchers and oncologists find the latest peer-reviewed research and reviews.

A convenient one-stop resource that:
- announces latest Articles-in-Press from Elsevier’s comprehensive portfolio of Oncology journals
- provides access to the new editions and archive of the EJC News Focus updates
- transmits free Podcasts from leading publications
- keeps you informed on industry meetings and events
- and much more...

Visit OncologyAdvance.com today.

ONE CLICK ACCESS TO ESSENTIAL RESOURCES IN ONCOLOGY
The experience of a digital-only programme

Do you wish searching through a scientific programme book could be as easy as googling? For ECC2015, we have replaced the printed programme with two platforms designed to serve all your needs. You can enjoy easy preparation for the Congress and an optimal, fulfilling experience throughout:

- Get an accurate programme at all times, including any last-minute changes
- Create your personalised programme selection
- Find out quickly and easily where you need to go for your chosen session
- Lighten your load: no book to carry around
- Know that you are helping our environment: together we avoid massive paper consumption!

Searchable Programme: browse on - www.europeancancercongress.org

- Search through all Congress days or narrow your enquiry to just one or two
- Create your ideal custom search by choosing your track and session type and throwing in a keyword or an author name
- Print your search results
- Create and print your own personal Congress programme

Mobile App: download on - www.europeancancercongress.org

- Get the latest Congress programme through our mobile app from May 2015
- Find your sessions of interest in seconds
- Create your custom Congress programme and export it to your own calendar – and be alerted by timely notifications
- Take your own notes throughout the event
- Easily share session information with your peers, via social media
- Use the interactive floor plan for immediate direction

Please note: no printed programme book will provided at the Congress

2015 Pezcoller Foundation-ECCO Recognition for Contribution to Oncology

Call for Nominations

ECCO – the European CanCer Organisation and the Pezcoller Foundation are pleased to announce the Call for Nominations for the 2015 Pezcoller Foundation-ECCO Recognition for Contribution to Oncology.

For 2015, in collaboration with ECCO – The European CanCer Organisation, the Pezcoller Foundation-ECCO Recognition for Contribution to Oncology will be awarded to a single individual for his/her professional life dedication to the improvement of cancer treatment, care and research. The award is open to all professions and specialties within the oncology field.

Nominations will be accepted for candidates irrespective of race, gender or nationality. Institutions, groups or associations are not eligible. Self-nominations will not be considered. Candidates must be nominated on the official form by one who is, or has been, affiliated with a university or medical institution.

A curriculum vitae and description of the candidate’s professional contribution to the field of oncology should be included with the application form.

Nominators are requested to keep their nomination confidential and to refrain from informing the nominee. The awardee will be selected by an International Committee appointed by the ECCO President with the agreement of the Council of the Pezcoller Foundation. The decision concerning the 2015 winner will be taken in April 2015.

The award consists of a prize of 30,000 EUR and a commemorative plaque. The Award Ceremonies will be held in Rovereto (Italy), on 11 September 2015 and in Vienna, during the 18th ECCO - 40th ESMO – European Cancer Congress as a Plenary Lecture to be delivered during the Presidential Session of Sunday 27 September 2015.

About the Pezcoller Foundation

The Pezcoller Foundation was established in 1980 through a most generous donation from Professor Alessio Pezcoller, a dedicated Italian surgeon, who devoted his life to his profession. Professor Pezcoller not only made important contributions to medicine but through his generosity and foresight, provided his lifetime’s savings for others to do likewise.

Formerly, until 1997, the Pezcoller Foundation presented an award in collaboration with the European School of Oncology (ESO). The Pezcoller Foundation-ECCO Recognition for Contribution to Oncology builds on this tradition.

About ECCO

ECCO – the European CanCer Organisation builds on this tradition.

More Information:
For more information about the nomination process and to submit a completed form and support documentation please contact Davi Kaur:
Tel: +32 2 775 29 31, Fax: +32 2 775 02 00, Email: davi.kaur@ecco-org.eu

Nomination forms can be downloaded at: www.ecco-org.eu (select “About ECCO” > “Awards”) and must be completed and received by 15 March 2015.
We take cancer personally

Patients are at the heart of everything we do at Roche. They motivate and inspire us to search for and develop innovative medicines and therapeutic solutions with the goal of transforming the lives of people with cancer around the globe.

We’ve come a long way, but there’s still a long way to go.
## Registration Fees

<table>
<thead>
<tr>
<th>Early Rate</th>
<th>Deadline: Tuesday 9 April 2015</th>
<th>ECC 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Rate Members</td>
<td></td>
<td>380</td>
</tr>
<tr>
<td>Early Rate Non Members</td>
<td></td>
<td>699</td>
</tr>
<tr>
<td>Early Rate Groups</td>
<td></td>
<td>699</td>
</tr>
<tr>
<td>Early Rate Junior Participants</td>
<td></td>
<td>175</td>
</tr>
<tr>
<td>Early Rate Emerging Economy</td>
<td></td>
<td>130</td>
</tr>
<tr>
<td>Early Rate Nurses Members</td>
<td></td>
<td>210</td>
</tr>
<tr>
<td>Early Rate Nurses Non-Members</td>
<td></td>
<td>375</td>
</tr>
<tr>
<td>Early Rate Patient Advocates</td>
<td></td>
<td>125</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Regular Rate</th>
<th>Deadline: Tuesday 4 August 2015</th>
<th>ECC 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular Rate Members</td>
<td></td>
<td>699</td>
</tr>
<tr>
<td>Regular Rate Non Members</td>
<td></td>
<td>999</td>
</tr>
<tr>
<td>Regular Rate Groups</td>
<td></td>
<td>999</td>
</tr>
<tr>
<td>Regular Rate Junior Participants</td>
<td></td>
<td>199</td>
</tr>
<tr>
<td>Regular Rate Emerging Economy</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>Regular Rate Nurses Members</td>
<td></td>
<td>355</td>
</tr>
<tr>
<td>Regular Rate Nurses Non-Members</td>
<td></td>
<td>485</td>
</tr>
<tr>
<td>Regular Rate Patient Advocates</td>
<td></td>
<td>150</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Late Rate</th>
<th>Deadline: Friday 18 September 2015</th>
<th>ECC 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Late Rate Members</td>
<td></td>
<td>999</td>
</tr>
<tr>
<td>Late Rate Non Members</td>
<td></td>
<td>1099</td>
</tr>
<tr>
<td>Late Rate Junior Participants</td>
<td></td>
<td>220</td>
</tr>
<tr>
<td>Late Rate Emerging Economy</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>Late Rate Nurses Members</td>
<td></td>
<td>460</td>
</tr>
<tr>
<td>Late Rate Nurses Non-Members</td>
<td></td>
<td>585</td>
</tr>
<tr>
<td>Late Rate Patient Advocates</td>
<td></td>
<td>170</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Onsite Rate</th>
<th>Deadline: As of 19 September 2015</th>
<th>ECC 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onsite Rate Members/Non Members</td>
<td></td>
<td>1199</td>
</tr>
<tr>
<td>Onsite Rate Nurses Members/Non Members</td>
<td></td>
<td>685</td>
</tr>
<tr>
<td>Onsite Rate Junior Participants</td>
<td></td>
<td>235</td>
</tr>
<tr>
<td>Onsite Rate Patient Advocates</td>
<td></td>
<td>190</td>
</tr>
<tr>
<td>Day rate</td>
<td></td>
<td>355</td>
</tr>
</tbody>
</table>
Exhibition & Sponsorship Opportunities

Showcase your latest scientific data through this uniquely powerful platform of European and global oncology science and clinical practice.

ECC2015 offers you a wide range of opportunities to achieve the highest level of exposure to a multidisciplinary audience from Europe and around the world.

A vast majority of Congress participants spends time in the Exhibition Hall with an overwhelming number expressly seeking product and technology updates.

The Congress provides you opportunities of proven effectiveness like Satellite Symposia, Exhibitor Spotlight Sessions and many others.

We look forward to working with you to identify and secure the items best suited to your objectives for your participation in ECC2015.

We look forward to greeting you in Vienna!

For information on sponsorship and exhibition opportunities, please contact:
Bruno De Man
Phone: +32 2 775 02 04
Email: bruno.deman@ecco-org.eu

To download the Invitation to Industry brochure and view the exhibition floor plan please visit the ECC2015 website at: www.europeancancercongress.org

General Information

Accommodation

Mondial Congress & Events has been appointed as the official local housing partner for the 18th ECCO – 40th ESMO European Cancer Congress and is offering hotel accommodation and other services for both groups and individuals.

Booking Accommodation for individuals are open since 1 October, 2014.

For all accommodation queries and information, please contact:

Mondial Congress & Events
Operngasse 20b
1040 Vienna, Austria
Tel: +43 1 58804 0
Fax: +43 1 58804 185
E-mail: ECC2015@mondial-congress.com

We kindly ask you to contact the appointed local housing partner directly. The Congress secretariat cannot provide accommodation-related information or handle any such related requests.

Congress Update Service

The Congress Update Service is the official electronic newsletter of the European Cancer Congress. It is specifically designed to share with you essential updates and notable developments in the lead up to the Congress.

Launching six months in advance, this monthly newsletter is sent to all registrants.

Please visit the website if you wish to subscribe:
www.europeancancercongress.org

ECCO and its Founding Members

As founding members of ECCO - the European CanCer Organisation - ESMO, ESTRO, ESSO, EACR, EONS and SIOPE have joined forces once again to create a powerful platform promoting multidisciplinarity. These organisations support a multidisciplinary approach as the ultimate way to ensure the best outcomes and quality of life for all cancer patients.
ECC2015 gives you the opportunity to:

- Join Society Sessions (see programme for full details)
- Attend Society General Assemblies (see programme for full details)
- Meet Society Secretariats at their exhibition stands
- Fast-track your Society membership application and renewal at each Society’s stand
- Network in a friendly professional environment and discuss in comfort all the exciting developments at ECC2015—all in your Society’s Exclusive Member Lounge

Insurance

The organisers do not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements regarding health and travel insurance.

Language and Translation

The official language of the Congress is English. No simultaneous translation will be provided.

Lunch and Refreshments

Lunch or refreshments are not included as part of the registration fee.

Official Carrier

Save up to 20% on travel with the Star Alliance network

The Star Alliance™ member airlines have been appointed as the Official Airline Network for the 18th ECCO—40th ESMO European Cancer Congress, Vienna, 25—29 September 2015.

Registered participants travelling to the event may qualify for a Star Alliance Conventions Plus discount of up to 20%, depending on fare and class of travel booked. To obtain the discount, please quote the event code: OS13S15 when calling the reservation office of a participating Star Alliance member airline.

For booking office information please visit:
www.staralliance.com/conventionsplus

The participating airlines for this event will be announced soon on the Congress website:

www.europeancancercongress.org

Discounts are offered on most published business and economy class fares, excluding website/internet fares, senior and youth fares, group fares and round the World fares.

Please note: For travel from Japan and New Zealand, special fares or discounts are offered by the participating airlines on their own network.

Networking at ECC2015

Meeting peers from a variety of disciplines and from all around the world is at the heart of the ECC2015 experience. The Congress will provide a variety of opportunities for delegates to interact, exchange ideas and share best practice. The Congress Update Service newsletter will provide more detailed information closer to the meeting.

Informal Networking Event

Take this opportunity to meet colleagues from all over the world in a relaxed, friendly environment. The Congress Informal Networking Event will take place on Monday 28 September as of 20:30 at the Volksgarten Clubdiskotheke, Burgring, A-1010 Vienna. Tickets can be purchased for 65 EUR at the time of registration or onsite at the Congress (subject to availability).

Transportation

With their Congress badges, delegates can travel for free with Vienna’s public transport system (25—29 September 2015). The Congress Centre Messe Wien is easy to reach both by public transportation and by car. It is conveniently located within just 10 minutes from Vienna’s city centre.

Messe Wien is well served by underground: line U2, station ‘Messe-Prater’, and by bus: lines 11A and 80B.

To reach Messe Wien by car, please use GPS destination 1020 Vienna, Ausstellungsstraße or Trabrennstraße.
BOOKING YOUR OWN CONFERENCE TRAVEL IS EASY AS ABC
WITH THE GLOBAL ONLINE BOOKING TOOL FROM STAR ALLIANCE CONVENTIONS PLUS

No matter where you are travelling from, the Star Alliance™ network offers you a wide choice of flights to the European Cancer Congress 2015 in Vienna, Austria.

And with over 18,500 flights a day to 1,316 destinations across 192 countries, our 27 member airlines extend the same choice to any future conferences you are planning to attend.

You can also save money when you book your flights. Simply quote the Convention Code OS13S15 and you plus one travelling companion will receive a special discount. Better still, no matter which Star Alliance member airline’s frequent flyer programme you belong to, you can earn and redeem miles across all 27 airlines.

For more information, or to join the airline network that offers you more choice wherever your conferences take you, simply go to www.staralliance.com/conventionsplus
Some tumor cells can evade the body’s immune response, which may result in disease progression\textsuperscript{2,3}

- One function of the body’s immune response is to detect and destroy tumor cells through activated T cells and other mechanisms; tumor cells express multiple antigens that are not expressed in normal tissue.\textsuperscript{1–3}

- However, some tumor cells may evade the body’s immune response by exploiting the PD-1 checkpoint pathway through expression of the dual PD-1 ligands PD-L1 and PD-L2.\textsuperscript{1,2,4–7}

- PD-L1 and PD-L2 engage the PD-1 receptor on T cells in order to inactivate T cells, which may allow tumor cells to evade the immune response.\textsuperscript{1,2,8}

MSD is committed to furthering the understanding of immunology in cancer, including the role of the PD-1 pathway.

Visit the MSD booth to learn more.

---

References: